  
1 
Worldwide emergence of resistance to antifungal drugs 
1 
challenges human health and food security 
2 
 
3 
Matthew C. Fisher1*, Nichola J. Hawkins2, Dominique Sanglard3 and Sarah J. Gurr4* 
4 
 
5 
1*Matthew C. Fisher, Faculty of Medicine, School of Public Health, Imperial College London, 
6 
W2 1PG, UK 
7 
2Nichola J. Hawkins, Biointeractions and Crop Protection, Rothamsted Research, Harpenden, 
8 
AL5 2JQ, UK 
9 
3Dominique Sanglard, Institute of Microbiology, University of Lausanne and University 
10 
Hospital, Lausanne CH-1011, Switzerland 
11 
4*Sarah J. Gurr, BioSciences, University of Exeter, EX4 4QD, UK and Utrecht University, 
12 
Paduallaan 8, The Netherlands 
13 
 
14 
*Corresponding authors: Matthew Fisher (matthew.fisher@imperial.ac.uk) and Sarah Gurr 
15 
(s.j.gurr@exeter.ac.uk) 
16 
 
17 
Short title: Fungicide resistance threatens health and crops 
18 
 
19 
One sentence summary: Emerging resistance to antifungal drugs and fungicides is 
20 
compromising our ability to treat fungal diseases in humans and in crops, necessitating new 
21 
approaches to control endemic and emerging infections. 
22 
 
23 
 
 
24 
  
2 
Abstract 
25 
We are witnessing an unprecedented rise in the rate of emergence of pathogenic fungi that 
26 
are resistant to the limited number of commonly used antifungal agents. For example, the 
27 
azoles are used for human and animal healthcare, for plant crop protection and in 
28 
antifouling coatings and timber preservation. The ubiquity and dual-use of azoles has 
29 
hastened the independent evolution of resistance in many environments. One consequence 
30 
is an increasing risk emerging from naturally occurring ‘opportunistic’ and antifungal 
31 
resistant pathogens, which challenge human healthcare. To avoid a global collapse in our 
32 
ability to control fungal infections and to avoid critical failures in healthcare and food 
33 
security, we must improve our stewardship of extant chemicals, promote novel antifungal 
34 
discovery and leverage emerging technologies for alternative solutions. 
35 
 
36 
Introduction 
37 
The rapid emergence of multidrug resistant pathogenic fungi and the better-publicised 
38 
threat of antibiotic resistant bacteria both pose a considerable threat to disease control 
39 
across diverse anthropogenic systems. These microbes respond adroitly to human-induced 
40 
natural selection through chemical treatments, and nimbly hijack human globalisation 
41 
pathways (1), so disseminating the problems world-wide. Today, crop-destroying fungi 
42 
account for perennial yield losses of around 20% worldwide, with a further 10% loss post-
43 
harvest. Fungal impacts on human health are currently spiralling and global mortality 
44 
caused by fungal diseases now exceeds that for malaria, or breast cancer, and is comparable 
45 
to tuberculosis and HIV (2). These infections have, hitherto, been greatly neglected relative 
46 
to other classes of infectious disease, despite occurring in more than a quarter of the 
47 
world’s population. 
48 
The first antifungal chemicals used in human healthcare, Nystatin and the polyenes, were 
49 
discovered in the 1950s, whilst copper and sulphur fungicides were first used to control crop 
50 
disease over 150 years ago. Today, systemic fungicides and antifungals are frontline 
51 
treatments for fungal diseases in both humans and plants. This control can, however, be 
52 
ephemeral as a result of the rapid development of resistance against the chemicals. Fungi 
53 
have highly plastic genomes and reproduce rapidly producing large populations. The 
54 
  
3 
combination of these properties quickly generates variants, selected for resistance. In plant 
55 
pathogens, the pace of breakdown is enhanced by monoculture cropping practices, as large 
56 
swathes of genetically uniform crops provide ideal feeding and breeding grounds for the 
57 
rapid emergence of fungicide-resistant variants. In humans, long periods of prophylactic 
58 
treatment in at-risk patients can similarly lead to the emergence of antifungal resistance (3). 
59 
Resistance to all licensed systemic antifungals has been documented in clinical pathogens, 
60 
although the rate of emergence varies between drug classes (Fig. 1) (3). Likewise, despite 
61 
the wider range of fungicides licenced for use in agriculture, resistance to each main class of 
62 
fungicides has emerged in some major pathogens (Fig. 1). This threat is exacerbated by the  
63 
additional threat of withdrawal of some chemical classes due to regulatory changes in, for 
64 
example the EU. 
65 
figure_1.ai  
66 
Antifungals for the treatment of fungal diseases in the clinic and the field 
67 
The chemical control of fungal pathogens that cause diseases in animals and crops has 
68 
progressed from the use of inorganic chemistries, through organic surface protectant 
69 
chemistries, to systemic-acting fungicides. There are approximately nine-fold more 
70 
antifungal compounds available to control crop diseases than to treat systemic animal 
71 
infections. Licenced treatments in humans are limited to four frontline classes of drugs (Fig. 
72 
1). The polyenes (such as amphotericin B) disrupt the structure of cell membranes by 
73 
sequestering the fungal membrane sterol ergosterol. The pyrimidine analogue 5-
74 
fluorocytosine (5-FC) blocks pyrimidine metabolism and DNA synthesis. The newest class of 
75 
antifungals, the echinocandins, inhibit (1-3)--D glucan synthase and disrupt cell wall 
76 
biosynthesis. The fourth and most widely used class of fungicides - the azoles, block 
77 
ergosterol biosynthesis through inhibition of lanosterol 14--demethylase. Most fungicides 
78 
for crop disease target mitochondrial function, the cytoskeleton, or ergosterol biosynthetic 
79 
pathways (Fig. 1), although some specialist chemistries, such as the aza-naphthalenes for 
80 
powdery mildew control, target other pathways.  
81 
  
4 
It is important to highlight that the azoles are the dominant chemistry in the treatment of 
82 
fungal infections in crops, humans and livestock, with 5 licenced clinical azole antifungals 
83 
and 31 for crop protection.  
84 
Parallel drivers of fungicide resistance in the clinic and the field 
85 
Human population growth, urbanisation and economic prosperity have fuelled demands for 
86 
increasing quantity and variety of food. Intensive agriculture has too often responded to this 
87 
demand with crops bred for maximum productivity under the protection of broad-scale 
88 
pesticide applications, inadvertently breeding out the plants’ own defences. In parallel, the 
89 
number of humans at risk from fungal infections is rising rapidly, as susceptible populations 
90 
increase, either through age, medical interventions or HIV infection. Medical advances 
91 
leading to greater initial survival of cancer or organ transplants can unfortunately leave 
92 
patients susceptible to secondary attack from opportunistic fungi, leading to increasing use 
93 
of antifungal drugs in clinical practice. Consequently, we are now witnessing an 
94 
unprecedented worldwide increase in antifungal resistance, through both space and time 
95 
(Fig. 2; Supp Table1). 
96 
Figure 2 lin.ai  
97 
The main drivers that underpin these changes are explored in Fig. 3. The global movement 
98 
of people and trade in produce has hastened the free-flow of fungal pathogens from 
99 
country to country, bringing new pathogens into contact with naïve hosts (1). In the clinical 
100 
setting, new species of multidrug resistant pathogenic fungi are emerging. Candida auris, 
101 
first described in Japan in 2009 following isolation from a patient’s ear, is responsible for a 
102 
rapidly increasing number of hospital-acquired invasive infections around the world (4). This 
103 
fungus is now resistant to all clinical antifungals (5) and presents a particular threat to 
104 
intensive-care units since it can survive normal decontamination protocols (6). The 
105 
emergence of resistance in Candida glabrata has coincided with this species becoming the 
106 
predominant bloodstream pathogen recovered from patients, due largely to the increasing 
107 
prophylactic use of echinocandins and azoles (7). There is also a growing threat from 
108 
filamentous pathogenic fungi which are intrinsically-resistant to a broad range of 
109 
antifungals; for example Aspergillus terreus (8), Scedosporium spp. (9), Fusarium spp (10) 
110 
and members of the mucorales (11). Simultaneously, we are witnessing the relentless 
111 
  
5 
emergence of new races of plant-infecting fungi able to overcome both host defences and 
112 
chemical treatments (12), as well as the evolution of these traits in existing major pathogens 
113 
(13)(14). The first case of resistance against the MBCs was reported in 1969 (15) and now 
114 
MBC resistance is known in over 90 plant pathogens (16). Azole resistance in a plant 
115 
pathogen was first reported in 1981 (17), but azole resistance is generally partial, in contrast 
116 
to the complete control failures seen for MBCs (18). QoI resistance was reported in field 
117 
trials even before commercial introduction, and in wider field populations within two years 
118 
of release (19). A new generation of SDHI fungicides has been introduced from 2007, but by 
119 
2017, resistant field isolates had been found in 17 pathogen species (20). Pathogens with 
120 
resistance against MBCs, azole, QoIs and SDHIs include the major wheat pathogen 
121 
Zymoseptoria tritici, banana black sigatoka pathogen Mycosphaerella fijiensis, cereal 
122 
powdery mildews Blumeria graminis, the emerging barley pathogen Ramularia collo-cygni 
123 
and the apple scab fungus Venturia inaequalis. In Botrytis cinerea (a generalist pathogen 
124 
that causes grey mould, particularly on soft fruits), resistance has been reported against 15 
125 
different classes of systemic and protectant fungicides (21). 
126 
figure3.ai  
127 
Parallel evolution of resistance mechanisms in the clinic and the field 
128 
The strong and highly specific selective pressure exerted on fungi by single-site-inhibiting 
129 
fungicides has resulted in similar adaptations arising over time in disparate fungal species. 
130 
Indeed, this parallel evolution extends across clinical and plant pathogenic fungi, with the 
131 
same key resistance mechanisms occurring independently in both. 
132 
Mutations resulting in conformation changes to the drug target site constitute the most 
133 
common resistance mechanism in pathogenic fungi. They have been reported in candin-
134 
resistant clinical pathogens; MBC, QoI and SDHI-resistant plant pathogens; and azole-
135 
resistant strains in field and clinic. A single mutation, G143A in cytochrome b, has emerged 
136 
in the field in over 20 species under selection by QoIs (14). Moreover, the Y137F 
137 
substitution in CYP51 has been found in multiple plant pathogens with partial azole 
138 
resistance, and Y132F occurs at the equivalent residue in C. albicans (22). Promoter changes 
139 
resulting in upregulation of the fungicide target are also common across clinical and plant 
140 
pathogenic fungi (23). In A. fumigatus, tandem repeats in the CYP51A promoter region 
141 
  
6 
occur together with downstream SNPs in the coding region, conferring a multi-azole 
142 
resistance phenotype (24). 
143 
A third resistance mechanism involves reducing intracellular drug accumulation, through 
144 
upregulation of efflux pumps. The upregulated efflux pumps may be ABC transporters or 
145 
major facilitators, and their upregulation may result from promoter insertions or 
146 
transcription factor gain-of-function mutations (3, 25).  
147 
Further resistance mechanisms have so far been identified only in clinical pathogens. 
148 
Activation of stress response pathways by Hsp90 can unleash cryptic diversity, potentiating 
149 
the evolution of resistance to azoles, echinocandins and polyenes in Candida and Aspergillus 
150 
species (26). Structural genomic plasticity can result in resistance, with chromosome arm 
151 
duplications leading to efflux pump and target-site overexpression in C. albicans (25, 27).  
152 
Hypermutator strains of C. glabrata and Cryptococcus were recently reported, with the 
153 
potential to evolve rapidly in response to host and drug selection (28, 29). 
154 
 
155 
Dual-use of azoles in the clinic and the field  
156 
The azoles are the most widely-deployed class of fungicides in crop protection, totalling, for 
157 
example, over 26% of all fungicides across the European Union (30). Azoles are also frontline 
158 
drugs that protect humans and animals against pathogenic fungi. However, dual-use may 
159 
have promoted azole resistance in an opportunistic pathogen of humans, threatening our 
160 
ability to use this important class of drugs (30, 31). The saprotroph Aspergillus fumigatus 
161 
colonises decaying vegetation in fields, forests and compost heaps and also infects 
162 
immunocompromised humans. Multi-azole-resistant A. fumigatus has been recovered from 
163 
both environmental and clinical samples across multiple continents. In the Netherlands, 
164 
over 25% of Aspergillus infections carry azole-resistance alleles. Azoles are increasingly 
165 
failing as frontline therapies, with associated patient mortality approaching 100% (32). 
166 
Population genomic analyses have shown that azole-resistant alleles in A. fumigatus are 
167 
associated with selective sweeps in regions of high azole-usage such as India (33). 
168 
Moreover, recombination also occurs, generating new combinations of azole-resistance 
169 
alleles (33). Investigations are now underway to assess the relative contributions of clinical 
170 
and environmental selection to azole-resistant A. fumigatus, and to identify the most 
171 
  
7 
problematic environmental applications of azoles. The potential conflict between the level 
172 
of agricultural use and the durability of clinical effectiveness of azoles highlights how limited 
173 
the antifungal toolbox is, where neither “side” can afford to lose a mode of action. Medicine 
174 
and food security are both vital to human health (34), and both fields are in urgent need of 
175 
a wider range of options to control fungal diseases. 
176 
 
177 
However, most cases of fungicide and antifungal resistance across field and clinic appear to 
178 
have arisen by the repeated independent evolution of resistance to successive fungicides 
179 
within numerous fungal species. This is where evolution of antifungal resistance differs 
180 
fundamentally from antibacterial resistance, which is frequently transferred between 
181 
animals and humans via the ‘mobilome’ of plasmids and phage (35). There is some evidence 
182 
of horizontal gene transfer among fungi, (36) but this occurs on longer timescales than gene 
183 
transfer among bacteria and the dynamics of resistance arising by this route is thus far 
184 
negligible. 
185 
 
186 
Prospects for diversifying the toolbox for fungal control 
187 
To counter the escalating risks of fungal disease we need to discover antifungal chemistries 
188 
with novel modes of action, hinder the emergence of resistance in extant chemistries by 
189 
better stewardship, and develop novel disease control strategies to avoid over-reliance on 
190 
fungicides: 
191 
Development of novel antifungals: The rate of emergence of fungicide resistance (Fig. 2) is 
192 
greater than the pace of fungicide discovery, and the long registration process for new 
193 
compounds adds further delays. This parallels the situation for antibiotics. There is thus a 
194 
need for increased research activity to develop new antifungal drugs (37). Recently, there 
195 
has been significant progress in this field, with at least 11 antifungals in Phase I-II clinical 
196 
trials and at least 2 in the AgChem pipeline.  Several of these are derivatives of commonly 
197 
used antifungal chemicals, such as ergosterol biosynthesis and cell wall biosynthesis 
198 
inhibitors, engineered for higher efficacy, whilst others have new modes of action. Further, 
199 
combining molecular modelling, combinatorial chemistry and high-throughput screening has 
200 
the potential to develop chemistries with reduced resistance risk due to the complexity of 
201 
the molecular changes required (38). 
202 
  
8 
Stewardship of existing compounds: Robust global strategies are needed to slow the 
203 
development of antifungal resistance. Combining different modes of action either in 
204 
mixtures, or as alternating treatments, may slow the emergence of resistance. A clinical trial 
205 
has shown that combinations of fluconazole, flucytosine and amphotericin-B can effectively 
206 
treat HIV-associated cryptococcal meningitis (39). In agriculture, mixtures of fungicides with 
207 
different modes of action are already widely recommended (40), with some formulations 
208 
only available as mixed products. Where target-site mutations confer high levels of 
209 
resistance lower doses of antifungals should be favoured (41, 42). However, this results in a 
210 
trade-off between immediate effectiveness of treatment and slowing the selection of 
211 
resistance. There is also a need to improve molecular diagnostics, both for the identification 
212 
of fungal pathogens so antifungals can be used appropriately, and for the detection of 
213 
specific resistance-alleles as the monitoring of resistance is a vital part of stewardship (43). 
214 
 
215 
Integrated disease management: To reduce our reliance on chemical control alone we must 
216 
develop more non-chemical control measures, to use where effective fungicides are no 
217 
longer available, or to use in combination with fungicides to reduce the selective pressure 
218 
on each component. In crops, the development of innate disease resistance through the 
219 
selection of major pathogen-resistant (R) alleles is widely used to breed disease resistant 
220 
cultivars. However, this approach is slow, with a 20 year lag from finding a suitable disease 
221 
resistance gene to releasing it in commercial lines. Marker-assisted breeding can speed up 
222 
the recombination of multiple disease resistance alleles, but still takes around a decade (44). 
223 
Transgene cloning or gene editing is faster still (circa 2 years), but no crops with transgenic 
224 
antifungal disease resistance have yet been released commercially. The high degree of 
225 
specificity between host and pathogen in major R genes (45) means pathogens can also 
226 
rapidly evolve to overcome this control measure. However, “evolution-smart” disease-
227 
resistant crops with pyramided pathogen resistance genes or mosaic deployment of 
228 
resistant varieties may provide greater durability of disease control. Minor resistance genes 
229 
(r), such as the antifungal chitinases and glucanases, carry the advantage of broad spectrum 
230 
activity (46), but suffer the possible disadvantage of yield penalties as well as incomplete 
231 
protection. Further sources of genetic disease resistance can be found in the gene pools of 
232 
crop wild relatives, which may be introduced to modern crop varieties through introgression 
233 
or transgenesis (44). 
234 
  
9 
 
235 
In humans, advances in combination anti-retroviral therapy to halt HIV-AIDS progression, 
236 
gene therapies under development for cystic fibrosis, or tissue engineering for rejection-free 
237 
transplants, can reduce vulnerability to fungal infections in such patient cohorts. Also, the 
238 
first antifungal vaccine,  against C. albicans, is undergoing clinical trials (47) and the use of 
239 
bioengineered T cells to augment host immunity is being explored (48). Finally, the 
240 
identification of human genetic biomarkers associated with susceptibility to fungal diseases, 
241 
for example PTX3 SNPs and A. fumigatus (49), provides a new path to identify patient groups 
242 
in which antifungal treatments could be reduced.  
243 
The rapidly growing fields of synthetic biology and epigenomics are converging on antifungal 
244 
treatments using RNA interference (RNAi). Bidirectional cross-kingdom microRNA (miRNA) 
245 
trafficking between plants and fungi is being developed as a novel strategy to tackle 
246 
pathogens (50), such as Botrytis cinerea which uses miRNA virulence effectors to silence 
247 
host plant immune genes (51, 52). Current research avenues include identifying new targets 
248 
for RNAi; and, crucially, developing systems for the stable and targeted delivery of RNA 
249 
silencing, through genetic engineering of the host plant or exogenous application of 
250 
synthetic RNA (51-53). Whilst such approaches have not yet been utilised to treat fungal 
251 
infections in the clinic, the discovery and use of RNAi as a clinical antifungal approach 
252 
represents a potentially transformational approach to tackling human fungal infections. 
253 
Conclusion 
254 
In both fungi and bacteria, the emergence of resistance has outpaced the supply of new 
255 
antimicrobial compounds. There is an urgent need to increase the pipeline of new active 
256 
compounds, to improve anti-resistance stewardship of existing products, and to diversify our 
257 
control toolbox with the development of novel non-chemical control methods. 
258 
 
259 
Acknowledgements: Professors Chris Thornton and Gero Steinberg for their critical 
260 
appraisal of the manuscript; Charlotte Gurr for infographics based on ideas by NJH; Alireza 
261 
Abdolrasouli for assistance with literature searches. Funding bodies; MCF was supported by 
262 
the Natural Environmental Research Council (NERC: NE/K014455/1) and the Medical 
263 
Research Council (MRC: MR/K000373/1): NJH through the BBSRC’s Industrial Strategy 
264 
  
10 
Challenge Fund (BBS/OS/CP/000001): DS by Swiss National Science Foundation (FN 
265 
301003A-172958) and SJG by BBSRC (BB/PO18335, awarded to Gero Steinberg and SJG) 
266 
Author contributions: MCF, NJH, DS, and SJG conceived and wrote the paper. 
267 
 
268 
References 
269 
 
270 
1. 
M. C. Fisher et al., Emerging fungal threats to animal, plant and ecosystem health. 
271 
Nature 484, 186-194 (2012). 
272 
2. 
G. D. Brown et al., Hidden Killers: Human Fungal Infections. Sci Transl Med 4,  (2012). 
273 
3. 
N. Robbins, T. Caplan, L. E. Cowen, Molecular Evolution of Antifungal Drug 
274 
Resistance. Annu Rev Microbiol 71, 753-775 (2017). 
275 
4. 
A. Chowdhary, C. Sharma, J. F. Meis, Candida auris: A rapidly emerging cause of 
276 
hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog 13, 
277 
e1006290 (2017). 
278 
5. 
S. R. Lockhart et al., Simultaneous Emergence of Multidrug-Resistant Candida auris 
279 
on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological 
280 
Analyses. Clin Infect Dis 64, 134-140 (2017). 
281 
6. 
S. Schelenz et al., First hospital outbreak of the globally emerging Candida auris in a 
282 
European hospital. Antimicrob Resist Infect Control 5, 35 (2016). 
283 
7. 
B. D. Alexander et al., Increasing Echinocandin Resistance in Candida glabrata: 
284 
Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum 
285 
Inhibitory Concentrations. Clin Infect Dis 56, 1724-1732 (2013). 
286 
8. 
R. Hachem et al., Invasive aspergillosis caused by Aspergillus terreus: an emerging 
287 
opportunistic infection with poor outcome independent of azole therapy. The 
288 
Journal of antimicrobial chemotherapy 69, 3148-3155 (2014). 
289 
9. 
M. Lackner et al., Species-specific antifungal susceptibility patterns of Scedosporium 
290 
and Pseudallescheria species. Antimicrob Agents Chemother 56, 2635-2642 (2012). 
291 
10. 
A. M. Al-Hatmi, F. Hagen, S. B. Menken, J. F. Meis, G. S. de Hoog, Global molecular 
292 
epidemiology and genetic diversity of Fusarium, a significant emerging group of 
293 
human opportunists from 1958 to 2015. Emerg Microbes Infect 5, e124 (2016). 
294 
  
11 
11. 
M. Slavin et al., Invasive infections due to filamentous fungi other than Aspergillus: 
295 
epidemiology and determinants of mortality. Clinical microbiology and infection : the 
296 
official publication of the European Society of Clinical Microbiology and Infectious 
297 
Diseases 21, 490 e491-410 (2015). 
298 
12. 
M. T. Islam et al., Emergence of wheat blast in Bangladesh was caused by a South 
299 
American lineage of Magnaporthe oryzae. Bmc Biol 14,  (2016). 
300 
13. 
M. S. Hovmoller et al., Replacement of the European wheat yellow rust population 
301 
by new races from the centre of diversity in the near-Himalayan region. Plant 
302 
Pathology 65, 402-411 (2016). 
303 
14. 
J. A. Lucas, N. J. Hawkins, B. A. Fraaije, The evolution of fungicide resistance. 
304 
Advances in Applied Microbiology 90, 29-92 (2015). 
305 
15. 
W. T. Schroeder, R. Provvidenti, Resistance to Benomyl in powdery mildew of 
306 
cucurbits. Plant Disease Reporter 53, 271-275 (1969). 
307 
16. 
N. J. Hawkins, B. A. Fraaije, Predicting resistance by mutagenesis: Lessons from 45 
308 
Years of MBC Resistance. Frontiers in Microbiology 7, 1814 (2016). 
309 
17. 
J. T. Fletcher, M. S. Wolfe, in British Crop Protection Conference- Pests and Diseases. 
310 
(BCPC, Brighton, 1981), vol. 2, pp. 633-640. 
311 
18. 
H. Cools, B. Fraaije, Are azole fungicides losing ground against Septoria wheat 
312 
disease? Resistance mecchansims in Mycosphaerella graminicola. Pest Management 
313 
Science 64, 681-684 (2008). 
314 
19. 
S. P. Heaney, A. Hall, S. A. Davies, G. Olaya, paper presented at the The BCPC 
315 
Conference - Pests and Diseases 2000,  . 
316 
20. 
Fungicide Resistance Action Committee. " List of plant pathogenic organisms 
317 
resistant to disease control agents" http://www.frac.info; Retrieved 23/01/2018 
318 
(2017). 
319 
21. 
M. Hahn, The rising threat of fungicide resistance in plant pathogenic fungi: Botrytis 
320 
as a case study. J Chem Biol 7, 133-141 (2014). 
321 
22. 
H. J. Cools, B. A. Fraaije, Are azole fungicides losing ground against Septoria wheat 
322 
disease? Resistance mechanisms in Mycosphaerella graminicola. Pest Manag Sci 64, 
323 
681-684 (2008). 
324 
  
12 
23. 
H. Hamamoto et al., Tandem repeat of a transcriptional enhancer upstream of the 
325 
sterol 14 alpha-demethylase gene (CYP51) in Penicillium digitatum. Appl Environ 
326 
Microb 66, 3421-3426 (2000). 
327 
24. 
E. Snelders et al., The structure-function relationship of the Aspergillus fumigatus 
328 
cyp51A L98H conversion by site-directed mutagenesis: the mechanism of L98H azole 
329 
resistance. Fungal Genet Biol 48, 1062-1070 (2011). 
330 
25. 
N. J. Hawkins et al., Paralog re-emergence: A novel, historically contingent 
331 
mechanism in the evolution of antimicrobial resistance. Mol. Biol. Evol. 31, 1793-
332 
1802 (2014). 
333 
26. 
L. E. Cowen, S. Lindquist, Hsp90 potentiates the rapid evolution of new traits: drug 
334 
resistance in diverse fungi. Science 309, 2185-2189 (2005). 
335 
27. 
A. Selmecki, M. Gerami-Nejad, C. Paulson, A. Forche, J. Berman, An isochromosome 
336 
confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1. Mol 
337 
Microbiol 68, 624-641 (2008). 
338 
28. 
J. Rhodes et al., A population genomics approach to assessing the genetic basis of 
339 
within-host microevolution underlying recurrent Cryptococcal meningitis infection. 
340 
G3 7, 1165-1176 (2017). 
341 
29. 
K. R. Healey et al., Prevalent mutator genotype identified in fungal pathogen Candida 
342 
glabrata promotes multi-drug resistance. Nat Commun 7, 11128 (2016). 
343 
30. 
European Centers for Disease Control. "Risk assessment on the impact of 
344 
environmental usage of triazoles on the development and spread of resistance to 
345 
medical triazoles in Aspergillus species"  (Stockholm, 2013). 
346 
31. 
J. F. Meis, A. Chowdhary, J. L. Rhodes, M. C. Fisher, P. E. Verweij, Clinical implications 
347 
of globally emerging azole resistance in Aspergillus fumigatus. Philos Trans R Soc 
348 
Lond B Biol Sci 371,  (2016). 
349 
32. 
J. van Paassen, A. Russcher, A. W. in t'Veld-van Wingerden, P. E. Verweij, E. J. 
350 
Kuijper, Emerging aspergillosis by azole-resistant Aspergillus fumigatus at an 
351 
intensive care unit in the Netherlands, 2010 to 2013. Eurosurveillance 21, 16-24 
352 
(2016). 
353 
33. 
A. Abdolrasouli et al., Genomic context of azole resistance mutations in Aspergillus 
354 
fumigatus determined using whole-genome sequencing. Mbio 6, e00536-00515 
355 
(2015). 
356 
  
13 
34. 
C. Swanton, H. Mashhadi, K. Solomon, M. Afifi, S. Duke, Similarities between the 
357 
discovery and regulation of pharmaceuticals and pesticides: in support of a better 
358 
understanding of the risks and benefits of each. Pest Management Science 67, 790-
359 
797 (2011). 
360 
35. 
T. A. Richards et al., Horizontal gene transfer facilitated the evolution of plant 
361 
parasitic mechanisms in the oomycetes. P Natl Acad Sci USA 108, 15258-15263 
362 
(2011). 
363 
36. 
J. A. Perry, G. D. Wright, The antibiotic resistance "mobilome": searching for the link 
364 
between environment and clinic. Front Microbiol 4,  (2013). 
365 
37. 
D. W. Denning, M. J. Bromley, How to bolster the antifungal pipeline. Science 347, 
366 
1414-1416 (2015). 
367 
38. 
J. L. Nishikawa et al., Inhibiting fungal multidrug resistance by disrupting an 
368 
activator-mediator interaction. Nature 530, 485-+ (2016). 
369 
39. 
M. Molefi et al., AMBITION-cm: intermittent high dose AmBisome on a high dose 
370 
fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan 
371 
Africa: study protocol for a randomized controlled trial. Trials 16, 276 (2015). 
372 
40. 
H. Dooley, M. W. Shaw, J. Spink, S. Kildea, Effect of azole fungicide mixtures, 
373 
alternations and dose on azole sensitivity in the wheat pathogen Zymoseptoria tritici. 
374 
Plant Pathology 65, 124-136 (2016). 
375 
41. 
F. van den Bosch, N. Paveley, M. Shaw, P. Hobbelen, R. Oliver, The dose rate debate: 
376 
does the risk of fungicide resistance increase or decrease with dose? Plant Pathology 
377 
60, 597-606 (2011). 
378 
42. 
A. Mikaberidze, N. Paveley, S. Bonhoeffer, F. van den Bosch, Emergence of resistance 
379 
to fungicides: The role of fungicide dose. Phytopathology 107, 545-560 (2017). 
380 
43. 
B. Barres et al., Trends and challenges in pesticide resistance detection. Trends Plant 
381 
Sci 21, 834-853 (2016). 
382 
44. 
S. Ashkani et al., Molecular breeding strategy and challenges towards improvement 
383 
of blast disease resistance in rice crop. Front Plant Sci 6,  (2015). 
384 
45. 
S. J. Gurr, P. J. Rushton, Engineering plants with increased disease resistance: what 
385 
are we going to express? Trends Biotechnol 23, 275-282 (2005). 
386 
  
14 
46. 
H. F. Eissa et al., Developing transgenic wheat to encounter rusts and powdery 
387 
mildew by overexpressing barley chi26 gene for fungal resistance. Plant Methods 13,  
388 
(2017). 
389 
47. 
J. Edwards, Fungal cell wall vaccines: an update. Journal of Medical Microbiology 61, 
390 
895-903 (2012). 
391 
48. 
P. R. Kumaresan et al., Bioengineering T cells to target carbohydrate to treat 
392 
opportunistic fungal infection. Proc Natl Acad Sci U S A 111, 10660-10665 (2014). 
393 
49. 
C. Cunha et al., Genetic PTX3 deficiency and aspergillosis in stem-cell 
394 
transplantation. N Engl J Med 370, 421-432 (2014). 
395 
50. 
M. Z. Ratajczak, J. Ratajczak, Horizontal transfer of RNA and proteins between cells 
396 
by extracellular microvesicles: 14 years later. Clin Transl Med 5,  (2016). 
397 
51. 
A. Weiberg et al., Fungal small RNAs suppress plant immunity by hijacking host RNA 
398 
interference pathways. Science 342, 118-123 (2013). 
399 
52. 
M. Wang et al., Bidirectional cross-kingdom RNAi and fungal uptake of external RNAs 
400 
confer plant protection. Nat Plants 2, 16151 (2016). 
401 
53. 
L. Kudsiova et al., Delivery of siRNA using ternary complexes containing branched 
402 
cationic peptides: the role of peptide sequence, branching and targeting. Mol Biosyst 
403 
12, 934-951 (2016). 
404 
 
405 
 
 
406 
  
15 
 
407 
Supplementary data references: 
408 
References in S Table1 
409 
 
410 
54. 
D. W. Denning et al., Itraconazole resistance in Aspergillus fumigatus. Antimicrob 
411 
Agents Chemother 41, 1364-1368 (1997). 
412 
55. 
E. Chryssanthou, In vitro susceptibility of respiratory isolates of Aspergillus species to 
413 
itraconazole and amphotericin B. acquired resistance to itraconazole. Scandinavian 
414 
journal of infectious diseases 29, 509-512 (1997). 
415 
56. 
E. Snelders et al., Emergence of azole resistance in Aspergillus fumigatus and spread 
416 
of a single resistance mechanism. PLoS medicine 5, e219 (2008). 
417 
57. 
C. Lazzarini et al., Azole Resistance in Aspergillus fumigatus Clinical Isolates from an 
418 
Italian Culture Collection. Antimicrob Agents Chemother 60, 682-685 (2016). 
419 
58. 
M. Tashiro et al., Antifungal susceptibilities of Aspergillus fumigatus clinical isolates 
420 
obtained in Nagasaki, Japan. Antimicrob Agents Chemother 56, 584-587 (2012). 
421 
59. 
S. J. Howard et al., Frequency and evolution of Azole resistance in Aspergillus 
422 
fumigatus associated with treatment failure. Emerging infectious diseases 15, 1068-
423 
1076 (2009). 
424 
60. 
E. Dannaoui et al., In-vitro susceptibility of Aspergillus spp. isolates to amphotericin B 
425 
and itraconazole. The Journal of antimicrobial chemotherapy 44, 553-555 (1999). 
426 
61. 
G. E. Ozmerdiven et al., First determination of azole resistance in Aspergillus 
427 
fumigatus strains carrying the TR34/L98H mutations in Turkey. Journal of infection 
428 
and chemotherapy : official journal of the Japan Society of Chemotherapy 21, 581-
429 
586 (2015). 
430 
62. 
A. Warris et al., Molecular epidemiology of Aspergillus fumigatus isolates recovered 
431 
from water, air, and patients shows two clusters of genetically distinct strains. J Clin 
432 
Microbiol 41, 4101-4106 (2003). 
433 
63. 
T. Pelaez et al., First detection of Aspergillus fumigatus azole-resistant strain due to 
434 
Cyp51A TR46/Y121F/T289A in an azole-naive patient in Spain. New microbes and 
435 
new infections 6, 33-34 (2015). 
436 
64. 
S. Seyedmousavi et al., Azole-resistant Aspergillus fumigatus, Iran. Emerging 
437 
infectious diseases 19, 832-834 (2013). 
438 
  
16 
65. 
S. E. Kidd, E. Goeman, J. F. Meis, M. A. Slavin, P. E. Verweij, Multi-triazole-resistant 
439 
Aspergillus fumigatus infections in Australia. Mycoses 58, 350-355 (2015). 
440 
66. 
A. Chowdhary et al., Isolation of multiple-triazole-resistant Aspergillus fumigatus 
441 
strains carrying the TR/L98H mutations in the cyp51A gene in India. The Journal of 
442 
antimicrobial chemotherapy 67, 362-366 (2012). 
443 
67. 
E. Vermeulen et al., Nationwide surveillance of azole resistance in Aspergillus 
444 
diseases. Antimicrob Agents Chemother 59, 4569-4576 (2015). 
445 
68. 
U. Nawrot et al., Detection of Polish clinical Aspergillus fumigatus isolates resistant 
446 
to triazoles. Med Mycol 56, 121-124 (2018). 
447 
69. 
K. M. Astvad et al., First detection of TR46/Y121F/T289A and TR34/L98H alterations 
448 
in Aspergillus fumigatus isolates from azole-naive patients in Denmark despite 
449 
negative findings in the environment. Antimicrob Agents Chemother 58, 5096-5101 
450 
(2014). 
451 
70. 
S. R. Lockhart et al., Azole resistance in Aspergillus fumigatus isolates from the 
452 
ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the 
453 
cyp51A gene. Antimicrob Agents Chemother 55, 4465-4468 (2011). 
454 
71. 
B. Bellete et al., Acquired resistance to voriconazole and itraconazole in a patient 
455 
with pulmonary aspergilloma. Med Mycol 48, 197-200 (2010). 
456 
72. 
O. Bader et al., cyp51A-Based mechanisms of Aspergillus fumigatus azole drug 
457 
resistance present in clinical samples from Germany. Antimicrob Agents Chemother 
458 
57, 3513-3517 (2013). 
459 
73. 
C. J. Wu et al., Azole-resistant Aspergillus fumigatus isolates carrying TR(34)/L98H 
460 
mutations in Taiwan. Mycoses 58, 544-549 (2015). 
461 
74. 
S. Ahmad, L. Joseph, F. Hagen, J. F. Meis, Z. Khan, Concomitant occurrence of 
462 
itraconazole-resistant and -susceptible strains of Aspergillus fumigatus in routine 
463 
cultures. The Journal of antimicrobial chemotherapy 70, 412-415 (2015). 
464 
75. 
A. Chowdhary et al., Multi-azole-resistant Aspergillus fumigatus in the environment 
465 
in Tanzania. Journal of Antimicrobial Chemotherapy 69, 2979-2983 (2014). 
466 
76. 
P. Le Pape, R. A. Lavergne, F. Morio, C. Alvarez-Moreno, Multiple fungicide-driven 
467 
alterations in Azole-resistant Aspergillus fumigatus, Colombia, 2015. Emerging 
468 
infectious diseases 22, 156-157 (2016). 
469 
  
17 
77. 
C. Sharma, F. Hagen, R. Moroti, J. F. Meis, A. Chowdhary, Triazole-resistant 
470 
Aspergillus fumigatus harbouring G54 mutation: Is it de novo or environmentally 
471 
acquired? Journal of global antimicrobial resistance 3, 69-74 (2015). 
472 
78. 
I. Perveen, S. Sehar, I. Naz, S. Ahmed, in Proceedings of the 7th Advances Against 
473 
Aspergillosis conference. (Manchester, UK, 2016), pp. 3–5 March 2016. 
474 
79. 
A. Riat, J. Plojoux, K. Gindro, J. Schrenzel, D. Sanglard, Azole resistance of 
475 
environmental and clinical Aspergillus fumigatus isolates from Switzerland. 
476 
Antimicrob Agents Chemother 62,  (2018). 
477 
80. 
S. S. Goncalves, Global aspects of triazole resistance in Aspergillus fumigatus with 
478 
focus on Latin American Countries. Journal of fungi (Basel, Switzerland) 3,  (2017). 
479 
81. 
J. F. Ryley, R. G. Wilson, K. J. Barrett-Bee, Azole resistance in Candida albicans. 
480 
Sabouraudia 22, 53-63 (1984). 
481 
82. 
A. Tavitian et al., Ketoconazole-resistant Candida esophagitis in patients with 
482 
acquired immunodeficiency syndrome. Gastroenterology 90, 443-445 (1986). 
483 
83. 
H. Dermoumi, In vitro susceptibility of yeast isolates from the blood to fluconazole 
484 
and amphotericin B. Chemotherapy 38, 112-117 (1992). 
485 
84. 
N. Troillet, C. Durussel, J. Bille, M. P. Glauser, J. P. Chave, Correlation between in 
486 
vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal 
487 
candidiasis in HIV-infected patients. European journal of clinical microbiology & 
488 
infectious diseases : official publication of the European Society of Clinical 
489 
Microbiology 12, 911-915 (1993). 
490 
85. 
A. Budak, Epidemiology of Candida infection. II. Application of biochemical methods 
491 
for typing of Candida albicans strains. Archivum immunologiae et therapiae 
492 
experimentalis 38, 369-377 (1990). 
493 
86. 
J. Dupouy-Camet et al., Resistance to fluconazole in hospitalized patients. 
494 
Concordance between Candida albicans resistance in vitro and therapeutic failure. 
495 
Presse medicale (Paris, France : 1983) 20, 1341 (1991). 
496 
87. 
F. Barchiesi et al., Fluconazole and ketoconazole in the treatment of oral and 
497 
esophageal candidiasis in AIDS patients. Journal of chemotherapy (Florence, Italy) 4, 
498 
381-386 (1992). 
499 
  
18 
88. 
F. Dronda, J. L. Rodriguez-Tudela, P. Mera, J. Martinez-Suarez, Esophagitis caused by 
500 
fluconazole-resistant Candida albicans: therapeutic failure and in vitro correlation. 
501 
Medicina clinica 99, 199 (1992). 
502 
89. 
T. G. Abrahamsen, E. Widing, A. Glomstein, P. Gaustad, Disseminated fungal disease 
503 
resistant to fluconazole treatment in a child with leukemia. Scandinavian journal of 
504 
infectious diseases 24, 391-393 (1992). 
505 
90. 
C. H. Hauman, I. O. Thompson, F. Theunissen, P. Wolfaardt, Oral carriage of Candida 
506 
in healthy and HIV-seropositive persons. Oral surgery, oral medicine, and oral 
507 
pathology 76, 570-572 (1993). 
508 
91. 
F. Allerberger et al., In vitro susceptibility of Candida albicans, Austria 1992. Mycoses 
509 
36, 411-416 (1993). 
510 
92. 
P. J. Gallagher et al., Reduced azole susceptibility of oral isolates of Candida albicans 
511 
from HIV-positive patients and a derivative exhibiting colony morphology variation. J 
512 
Gen Microbiol 138, 1901-1911 (1992). 
513 
93. 
Y. C. Chen, S. C. Chang, W. C. Hsieh, K. T. Luh, In vitro antifungal susceptibilities of 
514 
Candida species isolated from the blood. Int J Antimicrob Agents 7, 217-222 (1996). 
515 
94. 
E. Chryssanthou, J. Torssander, B. Petrini, Oral Candida albicans isolates with 
516 
reduced susceptibility to fluconazole in Swedish HIV-infected patients. Scandinavian 
517 
journal of infectious diseases 27, 391-395 (1995). 
518 
95. 
R. Rautemaa et al., Decreased susceptibility of Candida albicans to azole antifungals: 
519 
a complication of long-term treatment in autoimmune polyendocrinopathy-
520 
candidiasis-ectodermal dystrophy (APECED) patients. The Journal of antimicrobial 
521 
chemotherapy 60, 889-892 (2007). 
522 
96. 
A. Velegraki, D. Papalambrou, S. Soremi, N. J. Legakis, Variable antifungal 
523 
susceptibility of wild-type Candida albicans phenotypes from neutropenic hosts. 
524 
European journal of clinical microbiology & infectious diseases : official publication of 
525 
the European Society of Clinical Microbiology 15, 854-860 (1996). 
526 
97. 
G. F. Araj, N. K. Daher, Z. A. Tabbarah, Antifungal susceptibility of Candida isolates at 
527 
the American University of Beirut Medical Center. Int J Antimicrob Agents 10, 291-
528 
296 (1998). 
529 
  
19 
98. 
S. Fujita, Studies on microtiter broth dilution method for antifungal susceptibility 
530 
testing of yeast isolates from blood and cerebrospinal fluid. Rinsho byori. The 
531 
Japanese journal of clinical pathology 44, 373-378 (1996). 
532 
99. 
J. Meis, M. Petrou, J. Bille, D. Ellis, D. Gibbs, A global evaluation of the susceptibility 
533 
of Candida species to fluconazole by disk diffusion. Global Antifungal Surveillance 
534 
Group. Diagn Microbiol Infect Dis 36, 215-223 (2000). 
535 
100. K. C. Hazen et al., Comparison of the susceptibilities of Candida spp. to fluconazole 
536 
and voriconazole in a 4-year global evaluation using disk diffusion. J Clin Microbiol 
537 
41, 5623-5632 (2003). 
538 
101. K. N. Prasad et al., Role of yeasts as nosocomial pathogens & their susceptibility to 
539 
fluconazole & amphotericin B. The Indian journal of medical research 110, 11-17 
540 
(1999). 
541 
102. M. A. Pfaller et al., International surveillance of blood stream infections due to 
542 
Candida species in the European SENTRY Program: species distribution and 
543 
antifungal susceptibility including the investigational triazole and echinocandin 
544 
agents. SENTRY Participant Group (Europe). Diagn Microbiol Infect Dis 35, 19-25 
545 
(1999). 
546 
103. A. L. Colombo, D. Da Matta, L. P. De Almeida, R. Rosas, Fluconazole susceptibility of 
547 
Brazilian Candida isolates assessed by a disk diffusion method. The Brazilian journal 
548 
of infectious diseases : an official publication of the Brazilian Society of Infectious 
549 
Diseases 6, 118-123 (2002). 
550 
104. Z. Samra, M. Yardeni, N. Peled, J. Bishara, Species distribution and antifungal 
551 
susceptibility of Candida bloodstream isolates in a tertiary medical center in Israel. 
552 
European journal of clinical microbiology & infectious diseases : official publication of 
553 
the European Society of Clinical Microbiology 24, 592-595 (2005). 
554 
105. G. S. Bulmer, M. L. Marquez, L. Co-Barcelona, R. A. Fromtling, Yeasts and fluconazole 
555 
susceptibility in the Philippines. Mycopathologia 146, 117-120 (1999). 
556 
106. L. R. Asmundsdottir, H. Erlendsdottir, M. Gottfredsson, Increasing incidence of 
557 
candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol 40, 
558 
3489-3492 (2002). 
559 
  
20 
107. M. S. Ellabib, I. A. ElJariny, In vitro activity of 6 antifungal agents on Candida species 
560 
isolated as causative agents from vaginal and other clinical specimens. Saudi medical 
561 
journal 22, 860-863 (2001). 
562 
108. M. C. Arendrup et al., Seminational surveillance of fungemia in Denmark: notably 
563 
high rates of fungaemia and numbers of isolates with reduced azole susceptibility. J 
564 
Clin Microbiol 43, 4434-4440 (2005). 
565 
109. C. Tapia et al., Antifungal susceptibility for Candida albicans isolated from AIDS 
566 
patients with oropharyngeal and esophageal candidiasis: experience with Etest. 
567 
Revista medica de Chile 131, 515-519 (2003). 
568 
110. C. A. Enwuru et al., Fluconazole resistant opportunistic oro-pharyngeal Candida and 
569 
non-Candida yeast-like isolates from HIV infected patients attending ARV clinics in 
570 
Lagos, Nigeria. African health sciences 8, 142-148 (2008). 
571 
111. J. I. Yoo et al., National surveillance of antifungal susceptibility of Candida species in 
572 
South Korean hospitals. Med Mycol 47, 554-558 (2009). 
573 
112. L. O. Sanchez-Vargas et al., Oral Candida isolates colonizing or infecting human 
574 
immunodeficiency virus-infected and healthy persons in Mexico. J Clin Microbiol 43, 
575 
4159-4162 (2005). 
576 
113. E. M. Mokaddas, N. A. Al-Sweih, Z. U. Khan, Species distribution and antifungal 
577 
susceptibility of Candida bloodstream isolates in Kuwait: a 10-year study. Journal of 
578 
medical microbiology 56, 255-259 (2007). 
579 
114. A. Sellami et al., Antifungal susceptibility of bloodstream Candida isolates in Sfax 
580 
hospital: Tunisia. Mycopathologia 171, 417-422 (2011). 
581 
115. E. Skrodeniene, A. Dambrauskiene, A. Vitkauskiene, Susceptibility of yeasts to 
582 
antifungal agents in Kaunas University of Medicine Hospital. Medicina (Kaunas, 
583 
Lithuania) 42, 294-299 (2006). 
584 
116. C. M. Fernandez Andreu et al., In vitro susceptibility of Candida strains to fluconazole 
585 
and amphotericin B. Revista cubana de medicina tropical 59, 113-118 (2007). 
586 
117. A. Mulu et al., Frequent detection of 'azole' resistant Candida species among late 
587 
presenting AIDS patients in northwest Ethiopia. BMC infectious diseases 13, 82 
588 
(2013). 
589 
118. M. Mares, M. Mares, M. Rusu, Antifungal susceptibility of 95 yeast strains isolated 
590 
from oral mycoses in HIV-negative and HIV-positive patients. Bacteriologia, 
591 
  
21 
virusologia, parazitologia, epidemiologia (Bucharest, Romania : 1990) 53, 41-42 
592 
(2008). 
593 
119. G. Barada, R. Basma, R. A. Khalaf, Microsatellite DNA identification and genotyping 
594 
of Candida albicans from Lebanese clinical isolates. Mycopathologia 165, 115-125 
595 
(2008). 
596 
120. P. Badiee, A. Alborzi, M. A. Davarpanah, E. Shakiba, Distributions and antifungal 
597 
susceptibility of Candida species from mucosal sites in HIV positive patients. Archives 
598 
of Iranian medicine 13, 282-287 (2010). 
599 
121. J. Q. Farooqi et al., Invasive candidiasis in Pakistan: clinical characteristics, species 
600 
distribution and antifungal susceptibility. Journal of medical microbiology 62, 259-
601 
268 (2013). 
602 
122. F. Mutua, G. Revathi, J. M. Machoki, Species distribution and antifungal sensitivity 
603 
patterns of vaginal yeasts. East African medical journal 87, 156-162 (2010). 
604 
123. P. M. Dos Santos Abrantes, C. P. McArthur, C. W. Africa, Multi-drug resistant oral 
605 
Candida species isolated from HIV-positive patients in South Africa and Cameroon. 
606 
Diagn Microbiol Infect Dis 79, 222-227 (2014). 
607 
124. M. Hegazi, A. Abdelkader, M. Zaki, B. El-Deek, Characteristics and risk factors of 
608 
candidemia in paediatric intensive care unit of a tertiary care children's hospital in 
609 
Egypt. Journal of infection in developing countries 8, 624-634 (2014). 
610 
125. K. J. Mukasa et al., Antifungal susceptibility patterns of vulvovaginal Candida species 
611 
among women attending antenatal clinic at Mbarara Regional Referral Hospital, 
612 
South Western Uganda. British microbiology research journal 5, 322-331 (2015). 
613 
126. V. Arsic Arsenijevic et al., Candida bloodstream infections in Serbia: First multicentre 
614 
report of a national prospective observational survey in intensive care units. 
615 
Mycoses 61, 70-78 (2018). 
616 
127. A. J. Morris, K. Rogers, W. P. McKinney, S. A. Roberts, J. T. Freeman, Antifungal 
617 
susceptibility results of New Zealand yeast isolates, 2001-2015: Impact of recent CLSI 
618 
breakpoints and epidemiological cutoff values for Candida and other yeast species. 
619 
Journal of global antimicrobial resistance,  (2018). 
620 
128. S. R. Lockhart et al., Simultaneous emergence of multidrug-resistant Candida auris 
621 
on 3 continents confirmed by whole-genome sequencing and epidemiological 
622 
  
22 
analyses. Clinical infectious diseases : an official publication of the Infectious Diseases 
623 
Society of America 64, 134-140 (2017). 
624 
129. A. Chowdhary, C. Sharma, J. F. Meis, Candida auris: A rapidly emerging cause of 
625 
hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog 13, 
626 
e1006290 (2017). 
627 
130. S. Vallabhaneni et al., Investigation of the first seven reported cases of Candida 
628 
auris, a globally emerging invasive, multidrug-resistant fungus - United States, May 
629 
2013-August 2016. MMWR. Morbidity and mortality weekly report 65, 1234-1237 
630 
(2016). 
631 
131. C. M. Parra-Giraldo et al., First report of sporadic cases of Candida auris in Colombia. 
632 
International journal of infectious diseases : IJID : official publication of the 
633 
International Society for Infectious Diseases 69, 63-67 (2018). 
634 
132. M. Emara et al., Candida auris candidemia in Kuwait, 2014. Emerging infectious 
635 
diseases 21, 1091-1092 (2015). 
636 
133. S. Schelenz et al., First hospital outbreak of the globally emerging Candida auris in a 
637 
European hospital. Antimicrobial resistance and infection control 5, 35 (2016). 
638 
134. A. B. Arauz et al., Isolation of Candida auris from 9 patients in Central America: 
639 
Importance of accurate diagnosis and susceptibility testing. Mycoses 61, 44-47 
640 
(2018). 
641 
135. D. W. Warnock et al., Fluconazole resistance in Candida glabrata. Lancet 2, 1310 
642 
(1988). 
643 
136. M. C. Arilla et al., Vulvovaginal candidiasis refractory to treatment with fluconazole. 
644 
European journal of obstetrics, gynecology, and reproductive biology 44, 77-80 
645 
(1992). 
646 
137. F. Barchiesi, A. L. Colombo, D. A. McGough, M. G. Rinaldi, Comparative study of 
647 
broth macrodilution and microdilution techniques for in vitro antifungal 
648 
susceptibility testing of yeasts by using the National Committee for Clinical 
649 
Laboratory Standards' proposed standard. J Clin Microbiol 32, 2494-2500 (1994). 
650 
138. P. Chavanet et al., Cross-sectional study of the susceptibility of Candida isolates to 
651 
antifungal drugs and in vitro-in vivo correlation in HIV-infected patients. AIDS 
652 
(London, England) 8, 945-950 (1994). 
653 
  
23 
139. A. Spinillo et al., Frequency and significance of drug resistance in vulvovaginal 
654 
candidiasis. Gynecologic and obstetric investigation 38, 130-133 (1994). 
655 
140. J. Berenguer, V. Fernandez-Baca, R. Sanchez, E. Bouza, In vitro activity of 
656 
amphotericin B, flucytosine and fluconazole against yeasts causing bloodstream 
657 
infections. European journal of clinical microbiology & infectious diseases : official 
658 
publication of the European Society of Clinical Microbiology 14, 362-365 (1995). 
659 
141. P. Piemonte et al., Emergency of fluconazole-resistant infections by Candida krusei 
660 
and Candida glabrata in neutropenic patients. Revista medica de Chile 124, 1149 
661 
(1996). 
662 
142. K. P. Ng, T. L. Saw, S. L. Na, T. S. Soo-Hoo, Systemic Candida infection in University 
663 
hospital 1997-1999: the distribution of Candida biotypes and antifungal susceptibility 
664 
patterns. Mycopathologia 149, 141-146 (2001). 
665 
143. M. A. Ribeiro, R. Dietze, C. R. Paula, D. A. Da Matta, A. L. Colombo, Susceptibility 
666 
profile of vaginal yeast isolates from Brazil. Mycopathologia 151, 5-10 (2001). 
667 
144. P. R. Hsueh, L. J. Teng, P. C. Yang, S. W. Ho, K. T. Luh, Emergence of nosocomial 
668 
candidemia at a teaching hospital in Taiwan from 1981 to 2000: increased 
669 
susceptibility of Candida species to fluconazole. Microbial drug resistance 
670 
(Larchmont, N.Y.) 8, 311-319 (2002). 
671 
145. Y. Zer, I. Balci, G. Meric, Identification and antifungal susceptibility of Candida 
672 
isolated from intensive care unit patients. The new microbiologica 25, 489-494 
673 
(2002). 
674 
146. M. T. Mujica, J. L. Finquelievich, V. Jewtuchowicz, C. A. Iovannitti, Prevalence of 
675 
Candida albicans and Candida non-albicans in clinical samples during 1999-2001. 
676 
Revista Argentina de microbiologia 36, 107-112 (2004). 
677 
147. L. L. Oon, M. G. Yeo, Fluconazole susceptibility of Candida species in Singapore by 
678 
disc diffusion test. Annals of the Academy of Medicine, Singapore 31, 497-501 
679 
(2002). 
680 
148. D. Swinne et al., A one-year survey of candidemia in Belgium in 2002. Epidemiology 
681 
and infection 132, 1175-1180 (2004). 
682 
149. E. Chryssanthou, H. Cherif, B. Petrini, M. Kalin, M. Bjorkholm, Surveillance of triazole 
683 
susceptibility of colonizing yeasts in patients with haematological malignancies. 
684 
Scandinavian journal of infectious diseases 36, 855-859 (2004). 
685 
  
24 
150. M. Sojakova, D. Liptajova, M. Borovsky, J. Subik, Fluconazole and itraconazole 
686 
susceptibility of vaginal yeast isolates from Slovakia. Mycopathologia 157, 163-169 
687 
(2004). 
688 
151. G. St-Germain et al., Epidemiology and antifungal susceptibility of bloodstream 
689 
Candida isolates in Quebec: Report on 453 cases between 2003 and 2005. The 
690 
Canadian journal of infectious diseases & medical microbiology = Journal canadien 
691 
des maladies infectieuses et de la microbiologie medicale 19, 55-62 (2008). 
692 
152. J. H. Meurman et al., Prevalence and antifungal drug sensitivity of non-albicans 
693 
Candida in oral rinse samples of self-caring elderly. Gerodontology 28, 246-252 
694 
(2011). 
695 
153. A. Varma, K. J. Kwon-Chung, Heteroresistance of Cryptococcus gattii to fluconazole. 
696 
Antimicrob Agents Chemother 54, 2303-2311 (2010). 
697 
154. J. W. Cheong, J. McCormack, Fluconazole resistance in cryptococcal disease: 
698 
emerging or intrinsic? Med Mycol 51, 261-269 (2013). 
699 
155. W. Peetermans, H. Bobbaers, J. Verhaegen, J. Vandepitte, Fluconazole-resistant 
700 
Cryptococcus neoformans var gattii in an AIDS patient. Acta clinica Belgica 48, 405-
701 
409 (1993). 
702 
156. H. K. Tseng et al., Microbiological, epidemiological, and clinical characteristics and 
703 
outcomes of patients with cryptococcosis in Taiwan, 1997-2010. PLoS One 8, e61921 
704 
(2013). 
705 
157. R. S. Gutch et al., Antifungal susceptibility of clinical and environmental Cryptococcus 
706 
neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in 
707 
Central India. Brazilian journal of microbiology : [publication of the Brazilian Society 
708 
for Microbiology] 46, 1125-1133 (2015). 
709 
158. S. T. Tay, T. Tanty Haryanty, K. P. Ng, M. Y. Rohani, H. Hamimah, In vitro 
710 
susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii 
711 
and Cryptococcus gattii to five antifungal drugs. Mycoses 49, 324-330 (2006). 
712 
159. O. C. Favalessa et al., First description of phenotypic profile and in vitro drug 
713 
susceptibility of Cryptococcus spp yeast isolated from HIV-positive and HIV-negative 
714 
patients in State of Mato Grosso. Revista da Sociedade Brasileira de Medicina 
715 
Tropical 42, 661-665 (2009). 
716 
  
25 
160. F. Hagen, R. Hare Jensen, J. F. Meis, M. C. Arendrup, Molecular epidemiology and in 
717 
vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu 
718 
lato and Cryptococcus gattii sensu lato isolates from Denmark. Mycoses 59, 576-584 
719 
(2016). 
720 
161. W. Dongmo et al., In Vitro antifungal susceptibility of environmental isolates of 
721 
Cryptococcus spp. from the West Region of Cameroon. Ethiopian journal of health 
722 
sciences 26, 555-560 (2016). 
723 
162. K. G. Davey, E. M. Johnson, A. D. Holmes, A. Szekely, D. W. Warnock, In-vitro 
724 
susceptibility of Cryptococcus neoformans isolates to fluconazole and itraconazole. 
725 
The Journal of antimicrobial chemotherapy 42, 217-220 (1998). 
726 
163. M. A. Pfaller et al., In vitro activities of voriconazole, fluconazole, and itraconazole 
727 
against 566 clinical isolates of Cryptococcus neoformans from the United States and 
728 
Africa. Antimicrob Agents Chemother 43, 169-171 (1999). 
729 
164. A. Armengou, C. Porcar, J. Mascaro, F. Garcia-Bragado, Possible development of 
730 
resistance to fluconazole during suppressive therapy for AIDS-associated 
731 
cryptococcal meningitis. Clinical infectious diseases : an official publication of the 
732 
Infectious Diseases Society of America 23, 1337-1338 (1996). 
733 
165. J. Chandenier et al., In vitro activity of amphotericin B, fluconazole and voriconazole 
734 
against 162 Cryptococcus neoformans isolates from Africa and Cambodia. European 
735 
journal of clinical microbiology & infectious diseases : official publication of the 
736 
European Society of Clinical Microbiology 23, 506-508 (2004). 
737 
166. H. Yamaguchi et al., The in vitro antifungal activities of fluconazole against 
738 
pathogenic yeasts recently isolated from clinical specimens. The Japanese journal of 
739 
antibiotics 50, 799-805 (1997). 
740 
167. S. H. Alves, J. O. Lopes, J. M. Costa, C. Klock, Development of secondary resistance to 
741 
fluconazole in Cryptococcus neoformans isolated from a patient with AIDS. Revista 
742 
do Instituto de Medicina Tropical de Sao Paulo 39, 359-361 (1997). 
743 
168. P. Mondon et al., Heteroresistance to fluconazole and voriconazole in Cryptococcus 
744 
neoformans. Antimicrob Agents Chemother 43, 1856-1861 (1999). 
745 
169. M. K. Lee, D. Yong, M. Kim, M. N. Kim, K. Lee, Species distribution and antifungal 
746 
susceptibilities of yeast clinical isolates from three hospitals in Korea, 2001 to 2007. 
747 
The Korean journal of laboratory medicine 30, 364-372 (2010). 
748 
  
26 
170. Y. C. Chen et al., Increasing trend of fluconazole-non-susceptible Cryptococcus 
749 
neoformans in patients with invasive cryptococcosis: a 12-year longitudinal study. 
750 
BMC infectious diseases 15, 277 (2015). 
751 
171. A. Trpkovic, M. Pekmezovic, A. Barac, L. Crncevic Radovic, V. Arsic Arsenijevic, In 
752 
vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and 
753 
itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and 
754 
blood from patients in Serbia. Journal de mycologie medicale 22, 243-248 (2012). 
755 
172. C. C. Bii et al., Antifungal drug susceptibility of Cryptococcus neoformans from clinical 
756 
sources in Nairobi, Kenya. Mycoses 50, 25-30 (2007). 
757 
173. O. Dorneanu et al., Cryptococcus meningitis, five years of experience and literature 
758 
review. Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi 112, 
759 
100-103 (2008). 
760 
174. E. Dannaoui et al., Comparison of antifungal MICs for yeasts obtained using the 
761 
EUCAST method in a reference laboratory and the Etest in nine different hospital 
762 
laboratories. Clinical microbiology and infection : the official publication of the 
763 
European Society of Clinical Microbiology and Infectious Diseases 16, 863-869 (2010). 
764 
175. T. Bicanic, T. Harrison, A. Niepieklo, N. Dyakopu, G. Meintjes, Symptomatic relapse of 
765 
HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the 
766 
role of fluconazole resistance and immune reconstitution. Clinical infectious diseases 
767 
: an official publication of the Infectious Diseases Society of America 43, 1069-1073 
768 
(2006). 
769 
176. C. S. Matos, A. de Souza Andrade, N. S. Oliveira, T. F. Barros, Microbiological 
770 
characteristics of clinical isolates of Cryptococcus spp. in Bahia, Brazil: molecular 
771 
types and antifungal susceptibilities. European journal of clinical microbiology & 
772 
infectious diseases : official publication of the European Society of Clinical 
773 
Microbiology 31, 1647-1652 (2012). 
774 
177. A. B. Khyriem, S. Sujatha, S. C. Parija, Antifungal susceptibility of Cryptococcus 
775 
neoformans to amphotericin B and fluconazole. Indian journal of pathology & 
776 
microbiology 49, 307-308 (2006). 
777 
178. P. Escandon et al., Cryptococcosis in Colombia: results of the national surveillance 
778 
program for the years 2006-2010. Biomedica : revista del Instituto Nacional de Salud 
779 
32, 386-398 (2012). 
780 
  
27 
179. H. Wang et al., In vitro susceptibilities of yeast species to fluconazole and 
781 
voriconazole as determined by the 2010 National China Hospital Invasive Fungal 
782 
Surveillance Net (CHIF-NET) study. J Clin Microbiol 50, 3952-3959 (2012). 
783 
180. M. Seilmaier, A. Hecht, W. Guggemos, K. Rudisser, Cryptococcal meningoencephalitis 
784 
related to HIV infection with resistance to fluconazole, relapse, and IRIS. 
785 
Medizinische Klinik (Munich, Germany : 1983) 104, 58-62 (2009). 
786 
181. T. Kammalac Ngouana et al., Cryptoccocal meningitis in Yaounde (Cameroon) HIV 
787 
infected patients: Diagnosis, frequency and Cryptococcus neoformans isolates 
788 
susceptibility study to fluconazole. Journal de mycologie medicale 25, 11-16 (2015). 
789 
182. H. S. Chong, R. Dagg, R. Malik, S. Chen, D. Carter, In vitro susceptibility of the yeast 
790 
pathogen Cryptococcus to fluconazole and other azoles varies with molecular 
791 
genotype. J Clin Microbiol 48, 4115-4120 (2010). 
792 
183. W. Pan et al., Resistance of Asian Cryptococcus neoformans serotype A is confined to 
793 
few microsatellite genotypes. PLoS One 7, e32868 (2012). 
794 
184. M. E. Bosco-Borgeat et al., Amino acid substitution in Cryptococcus neoformans 
795 
lanosterol 14-alpha-demethylase involved in fluconazole resistance in clinical 
796 
isolates. Revista Argentina de microbiologia 48, 137-142 (2016). 
797 
185. T. J. Proffer et al., Occurrence, distribution, and polymerase chain reaction-based 
798 
detection of resistance to sterol demethylation inhibitor fungicides in populations of 
799 
Blumeriella jaapii in Michigan. Phytopathology 96, 709-717 (2006). 
800 
186. Z. G. Ma, D. P. Morgan, D. Felts, T. J. Michailides, Sensitivity of Botryosphaeria 
801 
dothidea from California pistachio to tebuconazole. Crop Protection 21, 829-835 
802 
(2002). 
803 
187. A. V. D. Pereira, R. B. Martins, S. J. Michereff, M. B. da Silva, M. P. S. Camara, 
804 
Sensitivity of Lasiodiplodia theobromae from Brazilian papaya orchards to MBC and 
805 
DMI fungicides. European Journal of Plant Pathology 132, 489-498 (2012). 
806 
188. Y. Elad, Reduced sensitivity of Botrytis cinerea to 2 sterol biosynthesis-inhibiting 
807 
fungicides - fenetrazole and fenethanil. Plant Pathology 41, 47-54 (1992). 
808 
189. C. Stehmann, M. A. DeWaard, Sensitivity of populations of Botrytis cinerea to 
809 
triazoles, benomyl and vinclozolin. European Journal of Plant Pathology 102, 171-180 
810 
(1996). 
811 
  
28 
190. P. Leroux, F. Chapeland, D. Desbrosses, M. Gredt, Patterns of cross-resistance to 
812 
fungicides in Botryotinia fuckeliana (Botrytis cinerea) isolates from French vineyards. 
813 
Crop Protection 18, 687-697 (1999). 
814 
191. C. Q. Zhang, J. W. Zhu, F. L. Wei, S. Y. Liu, G. N. Zhu, Sensitivity of Botrytis cinerea 
815 
from greenhouse vegetables to DMIs and fenhexamid. Phytoparasitica 35, 300-313 
816 
(2007). 
817 
192. V. Guarnaccia et al., Emergence of Prochloraz-resistant populations of Calonectria 
818 
pauciramosa and Calonectria polizzii in ornamental nurseries of Southern Italy. Plant 
819 
Disease 98, 344-350 (2013). 
820 
193. G. S. Karaoglanidis, P. M. Ioannidis, C. C. Thanassoulopoulos, Reduced sensitivity of 
821 
Cercospora beticola isolates to sterol-demethylation-inhibiting fungicides. Plant 
822 
Pathology 49, 567-572 (2000). 
823 
194. G. A. Secor, V. V. Rivera, M. F. R. Khan, N. C. Gudmestad, Monitoring fungicide 
824 
sensitivity of Cercospora beticola of sugar beet for disease management decisions. 
825 
Plant Disease 94, 1272-1282 (2010). 
826 
195. N. R. Trkulja et al., Molecular and experimental evidence of multi-resistance of 
827 
Cercospora beticola field populations to MBC, DMI and QoI fungicides. European 
828 
Journal of Plant Pathology 149, 895-910 (2017). 
829 
196. FRAC SBI Working Group. (Fungicide Resistance Action Committee, 2018). 
830 
197. K. L. Stevenson, P. F. Bertrand, T. B. Brenneman, Evidence for reduced sensitivity to 
831 
propiconazole in the pecan scab fungus in Georgia. Phytopathology 94, S99-S99 
832 
(2004). 
833 
198. B. Cuendis, Universidad de Costa Rica, San  José, Costa Rica (1988). 
834 
199. K.-C. Kuo, Sensitivity of mango anthracnose pathogen, Colletotrichum 
835 
gloeosporioides, to the fungicide prochloraz in Taiwan. Proceedings of the National 
836 
Science Council Republic of China Part B Life Sciences 25, 174-179 (2001). 
837 
200. J. G. Gutierrez-Alonso et al., Evaluation of resistance to Imazalil, Prochloraz and 
838 
Azoxystrobin of Colletotrichum gloeosporioides (Penz.) Penz. y Sacc. isolates, and 
839 
control of Mango (Mangifera indica L.) anthracnosis during Postharvest. Revista 
840 
Mexicana de Fitopatologia 21, 379-382 (2003). 
841 
  
29 
201. D. Chen, H. Shi, H. Wu, Z. Xu, C. Zhang, Resistance of Colletotrichum gloeosporioides 
842 
causing grape ripe rot to thiophanate-methyl and tebuconazole in Zhejiang. Journal 
843 
of Fruit Science 30, 665-668 (2013). 
844 
202. S. Chen, C. Luo, M. Hu, G. Schnabel, Characterization of resistance to DMI fungicides 
845 
in Colletotrichum spp. isolates from peach. Phytopathology 106, 71-72 (2016). 
846 
203. C. Zhang et al., Assessing the risk for resistance and elucidating the genetics of 
847 
Colletotrichum truncatum that is only sensitive to some DMI fungicides. Frontiers in 
848 
Microbiology 8, 11 (2017). 
849 
204. J. T. Fletcher, M. S. Wolfe, in British Crop Protection Conference- Pests and Diseases. 
850 
(BCPC, Brighton, 1981), vol. 2, pp. 633-640. 
851 
205. M. S. Wolfe et al., Barley mildew in Europe: population biology and host resistance. 
852 
Euphytica 63, 125-139 (1992). 
853 
206. K. I. Almughrabi, A. B. Gray, Competition between triadimefon-sensitive and 
854 
triadimefon-resistant isolates of Erysiphe graminis f.sp. tritici. Plant Disease 79, 709-
855 
712 (1995). 
856 
207. FRAC SBI Working Group. (Fungicide Resistance Action Committee, 2016). 
857 
208. H. Buchenauer, K. H. Hellwald, Resistance of Erysiphe graminis on barley and wheat 
858 
to sterol C-14-demethylation inhibitors1. EPPO Bulletin 15, 459-466 (1985). 
859 
209. M. A. De Waard, E. M. C. Kipp, N. M. Horn, J. G. M. Vannistelrooy, Variation in 
860 
sensitivity to fungicides which inhibit ergosterol biosynthesis in wheat powdery 
861 
mildew. Netherlands Journal of Plant Pathology 92, 21-32 (1986). 
862 
210. Fungicide Resistance Action Committee. " List of Plant Pathogenic Organisms 
863 
Resistant to Disease Control Agents" http://www.frac.info; Retrieved 23/01/2018 
864 
(2017). 
865 
211. M. Svec, M. Miklovicova, M. Sykora, E. Krippel, Fungicide sensitivity of populations of 
866 
wheat powdery mildew (Erysiphe graminis f.sp. tritici) in Central Europe in 1993. 
867 
Pesticide Science 43, 47-52 (1995). 
868 
212. Z. Ma et al., Monitoring resistance of wheat powdery mildew to triadimefon. Acta 
869 
Phytophylacica Sinica 24, 85-88 (1997). 
870 
213. R. A. Wyand, J. K. M. Brown, Sequence variation in the CYP51 gene of Blumeria 
871 
graminis associated with resistance to sterol demethylase inhibiting fungicides. 
872 
Fungal Genetics and Biology 42, 726-735 (2005). 
873 
  
30 
214. FRAC SBI Working Group. (Fungicide Resistance Action Committee, 2017). 
874 
215. E. A. Meyers, R. Whetten, C. Cowger, Variation in sensitivity to DMI fungicides 
875 
tebuconazole and prothioconazole in Blumeria graminis f.sp tritici. Phytopathology 
876 
107, 32-32 (2017). 
877 
216. J. D. Weems, C. A. Bradley, Sensitivity of Exserohilum turcicum to demethylation 
878 
inhibitor fungicides. Crop Protection 99, 85-92 (2017). 
879 
217. Y. Yin, X. Liu, B. Li, Z. Ma, characterization of sterol demethylation inhibitor-resistant 
880 
isolates of Fusarium asiaticum and F. graminearum collected from wheat in China. 
881 
Phytopathology 99, 487-497 (2009). 
882 
218. F. Talas, B. A. McDonald, Significant variation in sensitivity to a DMI fungicide in field 
883 
populations of Fusarium graminearum. Plant Pathology 64, 664-670 (2015). 
884 
219. P. Spolti, B. C. d. Jorge, E. M. Del Ponte, Sensitivity of Fusarium graminearum causing 
885 
head blight of wheat in Brazil to tebuconazole and metconazole fungicides. Tropical 
886 
Plant Pathology 37, 419-423 (2012). 
887 
220. P. Spolti, E. M. Del Ponte, Y. H. Dong, J. A. Cummings, G. C. Bergstrom, Sensitivity in a 
888 
contemporary population of Fusarium graminearum from New York wheat and 
889 
competitiveness of a tebuconazole-resistant isolate. Plant Disease 98, 607-613 
890 
(2014). 
891 
221. E. D. Nagygyorgy et al., Toxicity of abiotic stressors to Fusarium species: differences 
892 
in hydrogen peroxide and fungicide tolerance. Acta Microbiol. Immunol. Hung. 61, 
893 
189-208 (2014). 
894 
222. H. Yang, M. Ji, K. Yao, Z. Shu, Study on resistance of Fusarium moniliforme to 
895 
Prochloraz and its management. Acta Agriculturae Jiangxi 25, 94-96, 105 (2013). 
896 
223. M. A. Yaghmour, R. M. Bostock, J. E. Adaskaveg, T. J. Michailides, Propiconazole 
897 
sensitivity in populations of Geotrichum candidum, the cause of sour rot of peach 
898 
and nectarine, in California. Plant Disease 96, 752-758 (2012). 
899 
224. B. Sedlakova, A. Lebeda, Fungicide resistance in Czech populations of cucurbit 
900 
powdery mildews. Phytoparasitica 36, 272-289 (2008). 
901 
225. A. P. Van de Wouw et al., Identification of isolates of the plant pathogen 
902 
Leptosphaeria maculans with resistance to the triazole fungicide fluquinconazole 
903 
using a novel in planta assay. Plos One 12, 19 (2017). 
904 
  
31 
226. W. F. Liao et al., Molecular mechanisms of drug sensitivity of rice blast fungi 
905 
Magnaporthe grisea to triazoles in China. Fresenius Environ. Bull. 27, 320-326 (2018). 
906 
227. P. A. G. Elmer, M. Braithwaite, D. J. Saville, in Fungicide Resistance, S. Heaney et al., 
907 
Eds. (1994), pp. 93-95. 
908 
228. E. I. Zehr, L. A. Luszcz, W. C. Olien, W. C. Newall, J. E. Toler, Reduced sensitivity in 
909 
Monilinia fructicola to propiconazole following prolonged exposure in peach 
910 
orchards. Plant Disease 83, 913-916 (1999). 
911 
229. L. L. May-De Mio, Y. Luo, T. J. Michailides, Sensitivity of Monilinia fructicola from 
912 
Brazil to Tebuconazole, Azoxystrobin, and Thiophanate-Methyl and Implications for 
913 
Disease Management. Plant Disease 95, 821-827 (2011). 
914 
230. B. Egueen, P. Melgarejo, A. De Cal, Sensitivity of Monilinia fructicola from Spanish 
915 
peach orchards to thiophanate-methyl, iprodione, and cyproconazole: fitness 
916 
analysis and competitiveness. European Journal of Plant Pathology 141, 789-801 
917 
(2015). 
918 
231. R. A. Romero, T. B. Sutton, Sensitivity of Mycosphaerella fijiensis, causal agent of 
919 
Black Sigatoka of Banana, to Propiconazole. Phytopathology 87, 96-100 (1997). 
920 
232. L. Perez, A. Hernandez, L. Hernandez, M. Perez, Effect of trifloxystrobin and 
921 
azoxystrobin on the control of black Sigatoka (Mycosphaerella fijiensis Morelet) on 
922 
banana and plantain. Crop Protection 21, 17-23 (2002). 
923 
233. G. P. Canas-Gutierrez et al., Analysis of the CYP51 gene and encoded protein in 
924 
propiconazole-resistant isolates of Mycosphaerella fijiensis. Pest Management 
925 
Science 65, 892-899 (2009). 
926 
234. FRAC Banana Working Group. (Fungicide Resistance Action Committee, 2015). 
927 
235. P. Chong et al., in Modern Fungicides and Antifungal Compounds VI. Proceedings of 
928 
the 16th International Reinhardsbrunn Symposium April 25 -29, 2010, Friedrichroda, 
929 
Germany, H. W. Dehne et al., Eds. (DPG Spectrum Phytomedizin, Braunschweig, 
930 
Germany, 2010), pp. 217-222. 
931 
236. L. Martinez-Bolanos et al., fungicide resistance on Mycosphaerella fijiensis 
932 
populations of southeastern Mexico. Agrociencia 46, 707-717 (2012). 
933 
237. C. Guillermet, R. Le Guen, E. Foure, C. Cespedes, L. D. de Bellaire, Adaptation of the 
934 
forecasting system to control Black Leaf Streak Disease of banana in the specific 
935 
conditions of Dominican Republic. Fruits 69, 261-278 (2014). 
936 
  
32 
238. FRAC Banana Working Group. (Fungicide Resistance Action Committee, 2017). 
937 
239. J. Yamaguchi, M. Inada, M. Matsuzaki, Occurrence of DMI-fungicide-resistant isolates 
938 
of Mycovellosiella nattrassii Deighton, causal fungus of leaf mold of eggplant. 
939 
Japanese Journal of Phytopathology 66, 78-84 (2000). 
940 
240. J. W. Eckert, Penicillium digitatum biotypes with reduced sensitivity to imazalil. 
941 
Phytopathology 77, 1728-1728 (1987). 
942 
241. V. G. Bus, A. J. Bongers, L. A. Risse, Occurrence of Penicillium digitatum and 
943 
Penicillium italicum resistant to benomyl thiabendazole and imazalil on citrus fruit 
944 
from different geographic origins. Plant Disease 75, 1098-1100 (1991). 
945 
242. H. Hamamoto et al., PCR-based detection of sterol demethylation inhibitor-resistant 
946 
strains of Penicillium digitatum. Pest Management Science 57, 839-843 (2001). 
947 
243. M. Kellerman et al., Classification of imazalil resistance in an international collection 
948 
of Penicillium digitatum isolates. Canadian Journal of Plant Pathology 39, 133-137 
949 
(2017). 
950 
244. J. Wang et al., Novel mutations in CYP51B from Penicillium digitatum Involved in 
951 
Prochloraz resistance. J Microbiol 52,  (2014). 
952 
245. D. A. S. Pereira, B. A. McDonald, P. C. Brunner, Mutations in the CYP51 gene reduce 
953 
DMI sensitivity in Parastagonospora nodorum populations in Europe and China. Pest 
954 
Management Science 73, 1503-1510 (2017). 
955 
246. M. A. El-Goorani, H. M. El-Kasheir, M. T. Kabeel, A. A. Shoeib, Resistance to 
956 
benzimidazole fungicides of Penicillium italicum and Penicillium digitatum isolated 
957 
from packinghouses and orchards in egypt. Plant Disease 68, 100-102 (1984). 
958 
247. G. J. Holmes, J. W. Eckert, Sensitivity of Penicillium digitatum and P. italicum to 
959 
postharvest citrus fungicides in California. Phytopathology 89, 716-721 (1999). 
960 
248. L. J. Koga, I. O. N. Lopes, C. V. Godoy, Sensitivity monitoring of Phakopsora pachyrhizi 
961 
populations to triazoles in Brazil. H. W. Dehne et al., Eds., Modern fungicides and 
962 
antifungal compounds VI. 16th International Reinhardsbrunn Symposium, 
963 
Friedrichroda, Germany, April 25-29, 2010 (Deutsche Phytomedizinische Gesellschaft 
964 
e.V. Selbstverlag, 2011), pp. 211-216. 
965 
249. A. Sombardier, M. C. Dufour, D. Blancard, M. F. Corio-Costet, Sensitivity of 
966 
Podosphaera aphanis isolates to DMI fungicides: distribution and reduced cross-
967 
sensitivity. Pest Management Science 66, 35-43 (2010). 
968 
  
33 
250. P. Leroux, M. Gredt, Evolution of fungicide resistance in the cereal eyespot fungi 
969 
Tapesia yallundae and Tapesia acuformis in France. Pesticide Science 51, 321-327 
970 
(1997). 
971 
251. S. Parnell, C. A. Gilligan, J. A. Lucas, C. H. Bock, F. van den Bosch, Changes in fungicide 
972 
sensitivity and relative species abundance in Oculimacula yallundae and O. acuformis 
973 
populations (eyespot disease of cereals) in Western Europe. Plant Pathology 57, 509-
974 
517 (2008). 
975 
252. B. Robbertse, G. Holz, P. W. Crous, Sensitivity of South African Ramulispora 
976 
herpotrichoides isolates to carbendazim and ergosterol biosynthesis inhibitors. Plant 
977 
Pathology 45, 270-275 (1996). 
978 
253. P. S. Dyer, J. Hansen, A. Delaney, J. A. Lucas, Genetic control of resistance to the 
979 
sterol 14α-demethylase inhibitor fungicide prochloraz in the cereal eyespot 
980 
pathogen Tapesia yallundae. Applied and Environmental Microbiology 66, 4599-4604 
981 
(2000). 
982 
254. P. Matusinsky, I. Svacinova, A. Jonaviciene, L. Tvaruzek, Long-term dynamics of 
983 
causative agents of stem base diseases in winter wheat and reaction of Czech 
984 
Oculimacula spp. and Microdochium spp. populations to prochloraz. European 
985 
Journal of Plant Pathology 148, 199-206 (2017). 
986 
255. E. K. Krebs, Problematical control of chrysanthemum white rust Bekämpfung des 
987 
Weissen Chrysanthemenrostes problematisch. TASPO artenbaumagazin 6, 40-41 
988 
(1997). 
989 
256. R. T. A. Cook, First report in England of changes in the susceptibility of Puccinia 
990 
horiana, the cause of chrysanthemum white rust, to triazole and strobilurin 
991 
fungicides. Plant Pathology 50, 792-792 (2001). 
992 
257. R. A. Bayles, Yellow rust of wheat - survey of sensitivity to DMI fungicides in 1997. 
993 
HGCA Project Report, 7 pp. (1998). 
994 
258. G. Stammler, J. Cordero, A. Koch, M. Semar, S. Schlehuber, Role of the Y134F 
995 
mutation in cyp51 and overexpression of cyp51 in the sensitivity response of 
996 
Puccinia triticina to epoxiconazole. Crop Protection 28, 891-897 (2009). 
997 
259. G. d. S. Arduim, E. M. Reis, A. L. Barcellos, C. Turra, In vivo sensitivity reduction of 
998 
Puccinia triticina races, causal agent of wheat leaf rust, to DMI and QoI fungicides. 
999 
Summa Phytopathologica 38, 306-311 (2012). 
1000 
  
34 
260. H. E. Carter et al., Alterations in the predicted regulatory and coding regions of the 
1001 
sterol 14 alpha-demethylase gene (CYP51) confer decreased azole sensitivity in the 
1002 
oilseed rape pathogen Pyrenopeziza brassicae. Molecular Plant Pathology 15, 513-
1003 
522 (2014). 
1004 
261. J. E. Sheridan, D. K. Nendick, in Proceedings of the forty second New Zealand weed 
1005 
and pest control conference, Taranki Country Lodge, New Plymouth, August 8-10, 
1006 
1989. (New Zealand Weed and Pest Control Society Inc., 1989), pp. 221-224. 
1007 
262. S. J. Kendall, in Brighton Crop Protection Conference- Pests and Diseases. (BCPC, 
1008 
Brighton, 1986), vol. 2, pp. 539-546. 
1009 
263. T. L. Peever, M. G. Milgroom, Lack of correlation between fitness and resistance to 
1010 
sterol biosynthesis-inhibiting fungicides in Pyrenophora teres. Phytopathology 84, 
1011 
515-519 (1994). 
1012 
264. T. L. Peever, M. G. Milgroom, Inheritance of triadimenol resistance in Pyrenophora-
1013 
teres. Phytopathology 82, 821-828 (1992). 
1014 
265. G. F. Campbell, P. W. Crous, Fungicide sensitivity of South African net- and spot-type 
1015 
isolates of Pyrenophora teres to ergosterol biosynthesis inhibitors. Australasian Plant 
1016 
Pathology 31, 151-155 (2002). 
1017 
266. A. Baturo-Ciesniewska, A. Grabowski, D. Panka, Diversity in the polish isolates of 
1018 
Drechslera teres in spring barley as determined through morphological features, 
1019 
mating types, reaction to control agents and rapd markers. J. Plant Pathol. 94, 339-
1020 
351 (2012). 
1021 
267. W. J. Mair et al., Demethylase inhibitor fungicide resistance in Pyrenophora teres f. 
1022 
sp. teres associated with target site modification and inducible overexpression of 
1023 
Cyp51. Frontiers in Microbiology 7,  (2016). 
1024 
268. S. Reimann, H. B. Deising, Inhibition of efflux transporter-mediated fungicide 
1025 
resistance in Pyrenophora tritici-repentis by a derivative of 4 '-hydroxyflavone and 
1026 
enhancement of fungicide activity. Applied and Environmental Microbiology 71, 
1027 
3269-3275 (2005). 
1028 
269. O. O. Ajayi-Oyetunde, C. J. Butts-Wilmsmeyer, C. A. Bradley, Sensitivity of 
1029 
Rhizoctonia solani to succinate dehydrogenase inhibitor and demethylation inhibitor 
1030 
fungicides. Plant Disease 101, 487-495 (2016). 
1031 
  
35 
270. M. Agrawal, S. Sunder, Variations in sensitivity of Rhizoctonia solani AG-1  IA isolates 
1032 
from rice to carbendazim and hexaconazole. Journal of Mycology and Plant 
1033 
Pathology 43, 394 (2013). 
1034 
271. N. J. Hawkins et al., Paralog Re-Emergence: A novel, historically contingent 
1035 
mechanism in the evolution of antimicrobial resistance. Mol. Biol. Evol. 31, 1793-
1036 
1802 (2014). 
1037 
272. B. Robbertse, M. van der Rijst, I. M. R. van Aarde, C. Lennox, P. Crous, DMI sensitivity 
1038 
and cross-resistance patterns of Rhynchosporium secalis isolates from South Africa. 
1039 
Crop Protection 20, 97-102 (2001). 
1040 
273. P. C. Brunner, T. S. Stefansson, J. Fountaine, V. Richina, B. A. McDonald, A Global 
1041 
Analysis of CYP51 Diversity and Azole Sensitivity in Rhynchosporium commune. 
1042 
Phytopathology 106, 355-361 (2016). 
1043 
274. J. M. Vargas, Jr., R. Golembiewski, A. R. Detweiler, Reduced sensitivity of Sclerotinia 
1044 
homoeocarpa to DMI fungicides. Phytopathology 82, 1069 (1992). 
1045 
275. T. Hsiang, L. Yang, W. Barton, Baseline sensitivity and cross-resistance to 
1046 
demethylation-inhibiting fungicides in Ontario isolates of Sclerotinia homoeocarpa. 
1047 
European Journal of Plant Pathology 103, 409-416 (1997). 
1048 
276. M. Mocioni, M. L. Gullino, A. Garibaldi, Sensitivity of Sclerotinia homoeocarpa 
1049 
isolates from turfgrass in Italy to demethylation-inhibiting (DMI) fungicides and 
1050 
iprodione. Phytopathologia Mediterranea 50, 408-413 (2011). 
1051 
277. M. Chatzidimopoulos, A. C. Pappas, Epidemiology and control of Septoria pyricola in 
1052 
pear leaf and fruit. J. Plant Pathol. 98, 447-452 (2016). 
1053 
278. J. M. Calabro, R. A. Spotts, G. L. Grove, Preliminary studies on sweet cherry powdery 
1054 
mildew resistance to DMI's in the Pacific Northwest. Phytopathology 96, S18-S18 
1055 
(2006). 
1056 
279. H. Schepers, Persistence of resistance to fungicides in Sphaerotheca fuliginea. 
1057 
Netherlands Journal of Plant Pathology 90, 165-171 (1984). 
1058 
280. F. Huggenberger, M. A. Collins, G. Skylakakis, Decreased sensitivity of Sphaerotheca 
1059 
fuliginea to fenarimol and other ergosterol-biosynthesis inhibitors. Crop Protection 
1060 
3, 137-149 (1984). 
1061 
281. M. T. McGrath, Fungicide resistance in cucurbit powdery mildew: Experiences and 
1062 
challenges. Plant Disease 85, 236-245 (2001). 
1063 
  
36 
282. N. Ohtsuka, K. Sou, T. Amano, Y. Nakazawa, Y. Yamada, Sensitivity of cucumber 
1064 
powdery mildew fungus (Sphaerotheca fuliginea) to several fungicides. Journal of 
1065 
Pesticide Science 16, 271-273 (1991). 
1066 
283. R. G. Obrien, L. L. Vawdrey, R. J. Glass, Fungicide resistance in cucurbit powdery 
1067 
mildew (Sphaerotheca fuliginea) and its effect on field control. Australian Journal of 
1068 
Experimental Agriculture 28, 417-423 (1988). 
1069 
284. Jinyoung, Hongsunseong, Imjaeuk, K. Y. Park, H. G. Kim, Screening of fungicide 
1070 
resistance of Cucumber Powdery Mildew pathogen, Sphaerotheca fusca in Gyeonggi 
1071 
Province. Research in Plant Disease 14, 95-101 (2008). 
1072 
285. W. Goszczynski, J. Cimanowski, R. Bachnacki, First note on the occurrence of a strain 
1073 
of Sphaerotheca mors-uvae schw. berk. with decreased sensitivity to triadimefon. 
1074 
Fruit Science Reports (Skierniewice) 15, 181-184 (1988). 
1075 
286. M. Reuveni, Improved control of powdery mildew (Sphaerotheca pannosa) of 
1076 
nectarines in Israel using strobilurin and polyoxin B fungicides; mixtures with sulfur; 
1077 
and early bloom applications. Crop Protection 20, 663-668 (2001). 
1078 
287. H. X. Li, K. L. Stevenson, M. T. Brewer, Differences in sensitivity to a triazole fungicide 
1079 
among Stagonosporopsis species causing gummy stem blight of cucurbits. Plant 
1080 
Disease 100, 2106-2112 (2016). 
1081 
288. D. Debieu, M. F. Coriocostet, H. Steva, C. Malosse, P. Leroux, Sterol composition of 
1082 
the vine powdery mildew fungus, Uncinula necator - comparison of triadimenol-
1083 
sensitive and resistant strains. Phytochemistry 39, 293-300 (1995). 
1084 
289. R. C. Pearson, D. G. Riegel, Evaluation of fungicides for control of powdery mildew of 
1085 
grapes, 1989. Fungicide and Nematicide Tests 45, 74 (1990). 
1086 
290. C. Délye, F. Laigret, M. F. Corio-Costet, A mutation in the 14 alpha-demethylase gene 
1087 
of Uncinula necator that correlates with resistance to a sterol biosynthesis inhibitor. 
1088 
Applied and Environmental Microbiology 63, 2966-2970 (1997). 
1089 
291. S. Steinkellner, H. Redl, Sensitivity of Uncinula necator populations following DMI-
1090 
fungicide usage in Austrian vineyards. Bodenkultur 52, 293-299 (2001). 
1091 
292. F. Halleen, G. Holz, K. L. Pringle, Resistance in Uncinula necator to triazole fungicides 
1092 
in South African grapevines. South African Journal of Enology and Viticulture 21, 71-
1093 
80 (2000). 
1094 
  
37 
293. S. Savocchia, B. E. Stummer, T. J. Wicks, R. van Heeswijck, E. S. Scott, Reduced 
1095 
sensitivity of Uncinula necator to sterol demethylation inhibiting fungicides in 
1096 
southern Australian vineyards. Australasian Plant Pathology 33, 465-473 (2004). 
1097 
294. O. Frenkel, L. Cadle-Davidson, W. F. Wilcox, M. G. Milgroom, Mechanisms of 
1098 
resistance to an Azole fungicide in the grapevine powdery mildew fungus, Erysiphe 
1099 
necator. Phytopathology 105, 370-377 (2015). 
1100 
295. P. D. Hildebrand, C. L. Lockhart, R. J. Newbery, R. G. Ross, Resistance of Venturia 
1101 
inaequalis to bitertanol and other demethylation-inhibiting fungicides. Canadian 
1102 
Journal of Plant Pathology-Revue Canadienne De Phytopathologie 10, 311-316 
1103 
(1988). 
1104 
296. V. F. Stanis, A. L. Jones, Reduced sensitivity to sterol-inhibiting fungicides in field 
1105 
isolates of Venturia inaequalis. Phytopathology 75, 1098-1101 (1985). 
1106 
297. T. S. Thind, M. Clerjeau, J. M. Olivier, First observations on resistance in Venturia 
1107 
inaequalis and Guignardia bidwellii to ergosterol-biosynthesis inhibitors in France. 
1108 
1986 British Crop Protection Conference. Pests and Diseases. Vol. 2., 491-498 (1986). 
1109 
298. R. Fiaccadori, A. Gielink, J. Dekker, Sensitivity to inhibitors of sterol biosynthesis in 
1110 
isolates of Venturia inaequalis from Italian and Dutch orchards. European Journal of 
1111 
Plant Pathology 93, 285-287 (1987). 
1112 
299. F. D. Smith, W. Koller, D. M. Parker, Baseline-sensitivity of three populations of 
1113 
Venturia inaequalis to flusilazole. Phytopathology 79, 1171 (1989). 
1114 
300. H. G. Whelan, M. R. Butcher, R. E. Gaunt, Sensitivity of Venturia inaequalis (black 
1115 
spot) on apples to DMI fungicides in New Zealand. Proceedings of the NZ Plant 
1116 
Protection Conference 45, 289-294 (1992). 
1117 
301. J. Kloutvorova, M. Lansky, J. Kupkova, In vitro estimation of some Venturia inaequalis 
1118 
Cke. Aderh. isolate responses to some fungicides. Vedecke Prace Ovocnarske, 29-36 
1119 
(2001). 
1120 
302. B. Meszka, A. Bielenin, Decrease of Venturia inaequalis (Cook) Aderh. sensitivity to 
1121 
dodine and sterol demethylation inhibitor fungicides. Plant Protection Science 38, 
1122 
659-661 (2002). 
1123 
303. S. D. Hetherington, D. A. Gunning, Myclobutanil resistance in an isolate of Venturia 
1124 
inaequalis from New South Wales. Australasian Plant Pathology 32, 121-122 (2003). 
1125 
  
38 
304. X. M. Xu, L. Q. Gao, J. R. Yang, Are insensitivities of Venturia inaequalis to 
1126 
myclobutanil and fenbuconazole correlated? Crop Protection 29, 183-189 (2010). 
1127 
305. J. L. Henriquez S, O. V. Sarmiento, P. Alarcon C, Sensitivity of Venturia inaequalis 
1128 
Chilean isolates to difenoconazole, fenarimol, mancozeb, and pyrimethanil. Chilean 
1129 
Journal of Agricultural Research 71, 39-44 (2011). 
1130 
306. M. Stević, P. Vukša, I. Elezović, Resistance of Venturia inaequalis to demethylation 
1131 
inhibiting (DMI) fungicides. Žemdirbystė=Agriculture, 65-72 (2010). 
1132 
307. P. Mondino et al., Sensitivity of Venturia inaequalis to Trifloxystrobin and 
1133 
Difenoconazole in Uruguay. Journal of Phytopathology 163, 1-10 (2015). 
1134 
308. Y. Tomita, H. Ishii, Reduced sensitivity to fenarimol in Japanese field strains of 
1135 
Venturia nashicola. Pesticide Science 54, 150-156 (1998). 
1136 
309. H. J. Hims, HGCA Project Report No. 91. Monitoring sensitivity to the DMI group of 
1137 
fungicides in populations of the leaf blotch pathogen (Septoria tritici) and the glume 
1138 
blotch pathogen (Septoria nodorum) of winter wheat. HGCA Project Report No. 91. 
1139 
Monitoring sensitivity to the DMI group of fungicides in populations of the leaf blotch 
1140 
pathogen ( Septoria tritici) and the glume blotch pathogen ( Septoria nodorum) of 
1141 
winter wheat., 31 pp. (1994). 
1142 
310. P. C. Brunner, F. L. Stefanato, B. A. McDonald, Evolution of the CYP51 gene in 
1143 
Mycosphaerella graminicola: evidence for intragenic recombination and selective 
1144 
replacement. Molecular Plant Pathology 9, 305-316 (2008). 
1145 
311. I. Stergiopoulos, J. G. M. van Nistelrooy, G. H. J. Kema, M. A. De Waard, Multiple 
1146 
mechanisms account for variation in base-line sensitivity to azole fungicides in field 
1147 
isolates of Mycosphaerella graminicola. Pest Management Science 59, 1333-1343 
1148 
(2003). 
1149 
312. J. Zhan, F. L. Stefanato, B. A. McDonald, Selection for increased cyproconazole 
1150 
tolerance in Mycosphaerella graminicola through local adaptation and in response to 
1151 
host resistance. Molecular Plant Pathology 7, 259-268 (2006). 
1152 
313. S. Kildea et al., Sensitivity of Mycosphaerella graminicola populations in the Republic 
1153 
of Ireland to DMI and QoI fungicides. Aspects of Applied Biology, 59-64 (2006). 
1154 
314. G. Stammler et al., Frequency of different CYP51-haplotypes of Mycosphaerella 
1155 
graminicola and their impact on epoxiconazole-sensitivity and -field efficacy. Crop 
1156 
Protection 27, 1448-1456 (2008). 
1157 
  
39 
315. S. Boukef, B. A. McDonald, A. Yahyaoui, S. Rezgui, P. C. Brunner, Frequency of 
1158 
mutations associated with fungicide resistance and population structure of 
1159 
Mycosphaerella graminicola in Tunisia. European Journal of Plant Pathology 132, 
1160 
111-122 (2012). 
1161 
316. G. Stammler, M. Semar, Sensitivity of Mycosphaerella graminicola (anamorph: 
1162 
Septoria tritici) to DMI fungicides across Europe and impact on field performance. 
1163 
EPPO Bulletin 41, 149-155 (2011). 
1164 
317. A. Mehl, U. Krieg, A. Suty-Heinze, Mycosphaerella graminicola: relevance of in vitro 
1165 
sensitivity and cyp51 mutations for the field performance of DMI fungicides. H. W. 
1166 
Dehne et al., Eds., Modern fungicides and antifungal compounds VI. 16th 
1167 
International Reinhardsbrunn Symposium, Friedrichroda, Germany, April 25-29, 2010 
1168 
(2011), pp. 245-250. 
1169 
318. H. Sierotzki, R. Frey, C. Buitrago, J. Wullschleger, U. Gisi, Sensitivity of European 
1170 
Mycosphaerella graminicola populations to DMI fungicides. H. W. Dehne et al., Eds., 
1171 
Modern fungicides and antifungal compounds VI. 16th International Reinhardsbrunn 
1172 
Symposium, Friedrichroda, Germany, April 25-29, 2010 (2011), pp. 237-243. 
1173 
319. D. Strobel, R. Bryson, G. Stammler, M. Semar, A European overview of the sensitivity 
1174 
of Mycosphaerella graminicola ( Zymoseptoria tritici) to DMI fungicides in vitro and 
1175 
the relative impact on field performance. H. W. Dehne et al., Eds., Modern fungicides 
1176 
and antifungal compounds VII. Proceedings of the 17th International Reinhardsbrunn 
1177 
Symposium, April 21-25 2013, Friedrichroda, Germany (2014), pp. 257-262. 
1178 
320. L. K. Estep et al., Emergence and early evolution of fungicide resistance in North 
1179 
American populations of Zymoseptoria tritici. Plant Pathology 64, 961-971 (2015). 
1180 
321. A. Milgate, D. Adorada, B. Orchard, J. Pattemore, First report of resistance to DMI 
1181 
fungicides in Australian populations of the wheat pathogen Zymoseptoria tritici. 
1182 
Plant Disease 100, 522-522 (2016). 
1183 
322. T. M. Stewart, A. J. Perry, M. J. Evans, Resistance of Zymoseptoria tritici to 
1184 
azoxystrobin and epoxiconazole in the lower North Island of New Zealand. New 
1185 
Zealand Plant Protection 67, 304-313 (2014). 
1186 
323. T. M. Heick, A. F. Justesen, L. N. Jorgensen, Resistance of wheat pathogen 
1187 
Zymoseptoria tritici to DMI and QoI fungicides in the Nordic-Baltic region - a status. 
1188 
European Journal of Plant Pathology 149, 669-682 (2017). 
1189 
  
40 
324. L. N. Jorgensen et al., Four azoles' profile in the control of Septoria, yellow rust and 
1190 
brown rust in wheat across Europe. Crop Protection 105, 16-27 (2018). 
1191 
 
1192 
 
1193 
Figure Legends 
1194 
 
1195 
Figure 1. Current antifungal drug classes used against plant and animal fungal infections, 
1196 
and their known resistance mechanisms. There are six main classes of fungicides. These are 
1197 
the morpholines, which inhibit two target sites within the ergosterol biosynthetic pathway, 
1198 
Δ14-reductase and Δ8-Δ7-isomerase (this reduces the risk of target-site resistance, but their 
1199 
intrinsic antifungal activity spectrum is narrower); the azoles used also in animal infections), 
1200 
which target the ergosterol biosynthetic pathway; the MBCs (benzimidazoles), which 
1201 
interfere with the cytoskeleton by binding to β-tubulin, so preventing the assembly of 
1202 
microtubules; the QoIs (strobilurins), and SDHIs (succinate dehydrogenase inhibitors), which 
1203 
both inhibit the electron transfer chain of mitochondrial respiration, with the SDHIs 
1204 
inhibiting complex II (succinate dehydrogenase) and the QoIs inhibiting complex III 
1205 
(cytochrome b, Quinone outside binding pocket) and the anilinopyrimidines which may 
1206 
target mitochondrial signalling pathways.  
1207 
 
1208 
Figure 2. Fungal species with reported antifungal resistance, by country. Increasing colour 
1209 
intensity (red scale) reflects growing number of reports. Plant map reports spatio-temporal 
1210 
records of resistance of crop pathogens to azoles. Human map reports spatio-temporal 
1211 
records of resistance of the pathogens Aspergillus fumigatus; Candida albicans, C. auris and 
1212 
C. glabrata; and Cryptococcus gattii and C. neoformans to azoles. Database derived from 
1213 
peer-reviewed publications as of March 2018, reporting cases of resistance occurring up to 
1214 
2017 available in Supplementary Information 1. 
1215 
 
1216 
Figure 3. Evolutionary drivers of antifungal resistance: heritable variation, high reproductive 
1217 
output and differential survival. 
1218 
  
41 
 
1219 
 
1220 
Supplementary content 
1221 
Supplementary Table 1. Published reports of azole fungicide resistance in plant and clinical 
1222 
pathogens, as illustrated in Figure 2. Plant records comprise spatio-temporal reports 
1223 
(country and year) of resistance to azoles in any plant pathogen species. Human records 
1224 
comprise spatio-temporal reports (country and year) of azole resistance in the pathogens  
1225 
Candida albicans, C. glabrata, C. auris, Cryptococcus spp., and Aspergillus fumigatus. 
1226 
Database derived from peer-reviewed publications as of March 2018, reporting cases of 
1227 
resistance occurring up to 2017. 
1228 
  
1229 
Supplementary content 
1230 
 
1231 
Supplementary Table 1. Published reports of azole fungicide resistance in plant and clinical 
1232 
pathogens, as illustrated in Figure 2. Plant records comprise spatio-temporal reports 
1233 
(country and year) of resistance to azoles in any plant pathogen species. Human records 
1234 
comprise spatio-temporal reports (country and year) of azole resistance in the pathogens 
1235 
Aspergillus fumigatus; Candida albicans, C. auris and C. glabrata; and Cryptococcus gattii 
1236 
and C. neoformans. Database derived from peer-reviewed publications as of March 2018, 
1237 
reporting cases of resistance occurring up to 2017. 
1238 
 
1239 
Pathogen 
Country 
Year 1 
Reference 
Clinical pathogens 
 
 
 
Aspergillus 
fumigatus 
United States 
1989 
(54) 
 
Sweden  
1995 
(55) 
 
Netherlands 
1998 
(56) 
 
Italy 
1998 
(57) 
 
Japan 
1998 
(58) 
 
United Kingdom 
1999 
(59) 
 
France 
1999 
(60) 
 
Turkey 
2000 
(61) 
 
Norway 
2001 
(62) 
  
42 
 
Spain 
2003 
(63) 
 
Iran 
2003 
(64) 
 
Australia 
2004 
(65) 
 
India 
2005 
(66) 
 
Belgium  
2006 
(67) 
 
Poland 
2006 
(68) 
 
Denmark 
2007 
(69) 
 
China 
2008 
(70) 
 
Morocco 
2010 
(71) 
 
Germany 
2011 
(72) 
 
Taiwan 
2011 
(73) 
 
Kuwait 
2013 
(74) 
 
Tanzania 
2013 
(75) 
 
Colombia 
2015 
(76) 
 
Romania 
2015 
(77) 
 
Pakistan 
2016 
(78) 
 
Switzerland 
2016 
(79) 
 
Argentina 
2017 
(80) 
 
 
 
 
Candida albicans 
United Kingdom 
1984 
(81) 
 
USA 
1984 
(82) 
 
Germany 
1985 
(83) 
 
Switzerland 
1990 
(84) 
 
Poland 
1990 
(85) 
 
France 
1991 
(86) 
 
Italy 
1992 
(87) 
 
Spain 
1992 
(88) 
 
Scandinavia 
1992 
(89) 
 
South Africa 
1992 
(90) 
 
Austria 
1992 
(91) 
 
Ireland 
1992 
(92) 
 
China 
1994 
(93) 
 
Sweden 
1995 
(94) 
 
Finland 
1995 
(95) 
 
Greece 
1996 
(96) 
 
Lebanon 
1996 
(97) 
 
Japan 
1996 
(98) 
 
Argentina 
1997 
(99) 
 
Netherlands 
1997 
(99) 
 
Australia 
1997 
(99) 
 
Portugal 
1997 
(99) 
 
Thailand 
1997 
(99) 
 
Venezuela 
1997 
(99) 
 
Turkey 
1997 
(99) 
 
Czech Republic   
1997 
(100) 
 
Singapore 
1997 
(100) 
  
43 
 
India 
1997 
(101) 
 
Canada 
1997 
(102) 
 
Brazil 
1998 
(103) 
 
Israel 
1998 
(104) 
 
Philippines 
1998 
(105) 
 
Colombia 
1999 
(100) 
 
Ecuador  
1999 
(100) 
 
Hungary 
1999 
(100) 
 
Peru 
1999 
(100) 
 
Iceland 
1999 
(106) 
 
Malaysia  
2001 
(100) 
 
Russia 
2001 
(100) 
 
Slovakia  
2001 
(100) 
 
Libya 
2001 
(107) 
 
Saudi Arabia 
2001 
(107) 
 
Denmark 
2003 
(108) 
 
Chile 
2003 
(109) 
 
Nigeria 
2004 
(110) 
 
Korea 
2004 
(111) 
 
Mexico 
2005 
(112) 
 
Kuwait 
2005 
(113) 
 
Niger 
2005 
(110) 
 
Tunisia 
2006 
(114) 
 
Lithuania 
2006 
(115) 
 
Cuba 
2007 
(116) 
 
Ethiopia 
2008 
(117) 
 
Romania 
2008 
(118) 
 
Lebanon 
2008 
(119) 
 
Iran 
2008 
(120) 
 
Pakistan 
2009 
(121) 
 
Kenya 
2010 
(122) 
 
Cameroon 
2012 
(123) 
 
Egypt 
2013 
(124) 
 
Uganda 
2013 
(125) 
 
Serbia 
2015 
(126) 
 
New Zealand 
2015 
(127) 
 
 
 
 
Candida auris 
Japan 
2008 
(128) 
 
Pakistan 
2008 
(128) 
 
Korea 
2009 
(129) 
 
South Africa 
2012 
(128) 
 
India 
2012 
(128) 
 
Venezuela 
2012 
(128) 
 
USA 
2013 
(130) 
 
Colombia 
2013 
(131) 
 
Kuwait 
2014 
(132) 
  
44 
 
UK 
2015 
(133) 
 
Panama 
2016 
(134) 
 
Norway 
2016 
(129) 
 
Kenya 
2016 
(129) 
 
Spain 
2017 
(129) 
 
Germany 
2017 
(129) 
 
 
 
 
Candida glabrata 
Germany 
1985 
(83) 
 
UK 
1988 
(135) 
 
Switzerland 
1990 
(84) 
 
Ireland 
1991 
(136) 
 
USA 
1993 
(137) 
 
France 
1993 
(138) 
 
Italy 
1994 
(139) 
 
Spain 
1994 
(140) 
 
China 
1996 
(93) 
 
Japan 
1996 
(98) 
 
Chile 
1996 
(141) 
 
Greece 
1996 
(96) 
 
Lebanon 
1996 
(97) 
 
India 
1997 
(101) 
 
Netherlands 
1997 
(99) 
 
Australia 
1997 
(99) 
 
Portugal 
1997 
(99) 
 
Philippines 
1998 
(105) 
 
Israel 
1998 
(104) 
 
Iceland 
1999 
(106) 
 
Malaysia 
1999 
(142) 
 
Brazil 
1999 
(143) 
 
Taiwan 
1999 
(144) 
 
Turkey 
1999 
(145) 
 
Saudi Arabia 
2001 
(107) 
 
Argentina 
2001 
(146) 
 
Singapore 
2002 
(147) 
 
Belgium 
2002 
(148) 
 
Sweden 
2003 
(149) 
 
Denmark 
2003 
(108) 
 
Slovakia  
2004 
(150) 
 
Korea 
2004 
(111) 
 
Mexico 
2005 
(112) 
 
Kuwait 
2005 
(113) 
 
Nigeria 
2005 
(110) 
 
Canada 
2005 
(151) 
 
Lithuania 
2006 
(115) 
 
Iran 
2008 
(120) 
 
Tunisia 
2009 
(114) 
  
45 
 
Kenya 
2010 
(122) 
 
Finland 
2011 
(152) 
 
Uganda 
2013 
(125) 
 
New Zealand 
2015 
(127) 
 
 
 
 
Cryptococcus gattii 
USA 
1965 
(153) 
 
Colombia 
1989 
(153) 
 
France 
1993 
(154) 
 
Zambia 
1993 
(155) 
 
Taiwan 
1997 
(156) 
 
Canada 
1999 
(153) 
 
India 
2006 
(157) 
 
Malaysia 
2006 
(158) 
 
Brazil 
2009 
(159) 
 
Australia 
2010 
(153) 
 
Denmark 
2016 
(160) 
 
Cameroon 
2016 
(161) 
 
 
 
 
Cryptococcus 
neoformans 
UK 
1986 
(162) 
 
USA 
1992 
(163) 
 
Spain 
1994 
(164) 
 
Rwanda 
1994 
(165) 
 
Congo 
1994 
(165) 
 
Gabon 
1994 
(165) 
 
Japan 
1996 
(166) 
 
Uganda 
1996 
(162) 
 
Brazil 
1997 
(167) 
 
Cambodia 
1998 
(165) 
 
Israel 
1998 
(168) 
 
Italy 
1999 
(168) 
 
Korea 
2001 
(169) 
 
Taiwan 
2002 
(170) 
 
Serbia 
2002 
(171) 
 
Kenya 
2003 
(172) 
 
Romania 
2003 
(173) 
 
Kenya 
2003 
(172) 
 
France 
2003 
(174) 
 
South Africa 
2005 
(175) 
 
Brazil 
2006 
(176) 
 
India 
2006 
(157) 
 
India 
2006 
(177) 
 
Malaysia 
2006 
(158) 
 
Colombia 
2006 
(178) 
 
China 
2009 
(179) 
 
Germany 
2009 
(180) 
  
46 
 
Cameroon 
2009 
(181) 
 
Australia 
2010 
(182) 
 
Canada 
2010 
(182) 
 
Thailand 
2011 
(183) 
 
Argentina 
2015 
(184) 
 
Denmark 
2016 
(160) 
 
 
 
 
Plant pathogens 
 
 
 
Blumeriella jaapii 
1995 
USA 
(185) 
 
 
 
 
Botryosphaeria 
dothidea 
2000 
USA 
(186) 
 
 
 
 
Botryosphaeria 
theobromae 
2007 
Brazil 
(187) 
 
 
 
 
Botrytis cinerea 
 
1990 
Israel 
(188) 
 
1992 
Germany 
(189) 
 
1997 
France  
(190) 
 
2006 
China 
(191) 
 
 
 
 
Calonectria 
pauciramosa 
 
2009 
Italy 
(192) 
 
 
 
 
Calonectria polizzi 
 
2009 
Italy 
(192) 
 
 
 
 
Cercospora beticola 
1995 
Greece 
(193) 
 
2002 
USA 
(194) 
 
2007 
Serbia 
(195) 
 
2012 
Germany 
(196) 
 
2012 
France 
(196) 
 
2013 
Italy 
(196) 
 
2013 
Switzerland 
(196) 
 
 
 
  
Cladosporium 
caryigenum 
2003 
USA 
(197) 
 
 
 
  
Colletotrichum 
gloeosporioides 
 
1988 
Costa Rica 
(198) 
 
2001 
Taiwan  
(199) 
 
2003 
Mexico 
(200) 
 
2013 
China 
(201) 
  
47 
 
 
 
  
Colletotrichum 
nymphaeae 
 
2016 
USA 
(202) 
 
 
 
  
Colletotrichum 
truncatum 
 
2013 
China 
(203) 
 
2016 
USA 
(202) 
 
 
 
  
Erysiphe graminis f. 
sp. hordeii 
 
1980 
UK 
(204) 
 
1990 
Italy 
(205) 
 
1990 
Spain 
(205) 
 
1990 
Austria 
(205) 
 
1990 
Germany 
(205) 
 
1990 
Poland  
(205) 
 
1990 
Switzerland 
(205) 
 
1990 
France 
(205) 
 
1990 
Czech 
Republic/Slovakia 
(205) 
 
1990 
Denmark 
(205) 
 
1991 
Canada 
 
(206) 
 
2014 
Australia 
(207) 
 
 
 
  
Erysiphe graminis f. 
sp. tritici 
 
1981 
Germany 
(208) 
 
1982 
Netherlands 
(209) 
 
1991 
France 
(210) 
 
1993 
Czech Republic 
(211) 
 
1993 
Austria  
(211) 
 
1993 
Hungary 
(211) 
 
1993 
Slovakia 
(211) 
 
1994 
China 
(212) 
 
1997 
UK 
(213) 
 
2009 
Australia 
(214) 
 
2013 
USA 
(215) 
 
2016 
Belgium 
(214) 
 
2016 
Poland  
(214) 
 
 
 
  
Exserohilum turcicim 
2009 
USA 
(216) 
 
 
 
  
Fusarium asiaticum 
2007 
China 
(217) 
 
 
 
  
  
48 
Fusarium 
graminearum 
2008 
China 
(217) 
 
2008 
Germany 
(218) 
 
2010 
Brazil 
(219) 
 
2011 
Italy 
(218) 
 
2011 
USA 
(220) 
 
2014 
Hungary 
(221) 
 
 
 
  
Fusarium 
moniliforme 
2013 
China 
(222) 
 
 
 
  
Geotrichum 
candidum 
2007 
USA 
(223) 
 
 
 
  
Golovinomyces 
cichoracearum 
2002 
Czech Republic 
(224) 
 
 
 
  
Leptosphaeria 
maculans 
 
2013 
Australia 
(225) 
Magnaporthe grisea 
2017 
China 
(226) 
 
 
 
  
Monilinia fructicola 
 
1992 
New Zealand 
(227) 
 
1995 
USA 
(228) 
 
2008 
Brazil 
(229) 
 
2010 
Spain 
(230) 
 
 
 
  
Mycosphaerella 
fijiensis 
1994 
Costa Rica 
(231) 
 
2000 
Cuba 
(232) 
 
2008 
Colombia 
(233) 
 
2009 
Honduras 
(234) 
 
2009 
Guatemala 
(234) 
 
2010 
Ecuador 
(235) 
 
2010 
Mexico 
(236) 
 
2011 
Dominican 
Republic 
(237) 
 
2012 
Philippines 
(234) 
 
2014 
Belize 
(234) 
 
2014 
Panama 
(234) 
 
2016 
Cameroon 
(238) 
 
2016 
Ivory Coast 
(238) 
 
 
 
  
Mycosphaerella 
musicola 
2014 
Australia 
(234) 
  
49 
 
 
 
 
  
Mycovellosiella 
nattrassii 
 
1998 
Japan 
(239) 
 
 
 
  
Penicillium 
digitatum 
 
1986 
USA 
(240) 
 
1989 
Argentina 
(241) 
 
1989 
Cyprus 
(241) 
 
1989 
Greece 
(241) 
 
1989 
Israel 
(241) 
 
1989 
Italy 
(241) 
 
1989 
Morocco 
(241) 
 
1989 
Spain 
(241) 
 
1989 
Uruguay 
(241) 
 
1990 
Japan 
(242) 
 
2011 
South Africa 
(243) 
 
2011 
Chile 
(243) 
 
2011 
Australia 
(243) 
 
2013 
China 
(244) 
 
 
 
  
Parastagonospora 
nodorum 
1994 
Switzerland 
(245) 
 
2001 
China 
(245) 
 
2005 
Denmark 
(245) 
 
2005 
Sweden 
(245) 
 
 
 
(53) 
Penicillium italicum 
1983 
Egypt 
(246) 
 
1989 
Morocco  
(241) 
 
1989 
Turkey  
(241) 
 
1989 
Uruguay 
(241) 
 
1994 
USA 
(247) 
 
 
 
  
Phakopsora 
pachyrhizi 
2009 
Brazil 
(248) 
 
 
 
  
Podosphaera 
aphanis 
2006 
France   
(249) 
 
 
 
  
Pseudocercosporella 
herpotrichoides var. 
herpotrichoides 
1985 
France 
(250) 
 
1986 
Germany 
(251) 
 
1986 
UK 
(251) 
  
50 
 
1992 
South Africa 
(252) 
 
2000 
New Zealand 
(253) 
 
2015 
Czech Republic 
(254) 
 
 
 
  
Pseudocercosporella 
herpotrichoides var. 
acuformis 
1984 
Germany 
(251) 
 
1986 
UK 
(251) 
 
1986 
France 
(251) 
 
 
 
  
Puccinia horiana 
1992 
Netherlands 
(210) 
 
1997 
Germany 
(255) 
 
1999 
UK 
(256) 
 
 
 
  
Puccinia striiformis 
1997 
UK 
(257) 
 
 
 
  
 
 
 
  
Puccinia triticina 
1997 
France 
(258) 
 
1997 
Germany 
(258) 
 
1997 
UK 
(258) 
 
2007 
Brazil 
(259) 
 
 
 
  
Pyrenopeziza 
brassicae 
2003 
UK 
(260) 
 
 
 
  
 
1984 
New Zealand 
(261) 
Pyrenophora teres 
1986 
UK 
(262) 
 
1991 
USA 
(263) 
 
1991 
Germany 
(263) 
 
1992 
Canada 
(264) 
 
1996 
South Africa 
(265) 
 
2007 
Poland 
(266) 
 
2013 
Australia 
(267) 
 
2017 
France 
(196) 
 
 
 
  
Pyrenophora tritici-
repentis 
1990 
Germany 
(268) 
 
 
 
  
 
 
 
  
Ramularia collo-
cygni 
2015 
Germany 
(207) 
 
2016 
Denmark 
(214) 
 
2016 
Sweden 
(214) 
 
2017 
Ireland 
(196) 
 
2017 
Belgium 
(196) 
 
2017 
France 
(196) 
  
51 
 
2017 
Austria 
(196) 
 
2017 
UK 
(196) 
 
 
 
 
Rhizoctonia solani 
2011 
USA 
(269) 
 
2013 
India 
(270) 
 
 
 
  
Rhynchosporium 
commune 
1985 
UK 
(271) 
 
1988 
New Zealand 
(261) 
 
1995 
South Africa 
(272) 
 
1999 
Switzerland 
(273) 
 
2005 
Spain 
(273) 
 
2008 
France 
(271) 
 
 
 
  
Sclerotinia 
homoeocarpa 
1992 
USA 
(274) 
 
1994 
Canada 
(275) 
 
2001 
Italy 
(276) 
 
 
 
  
Septoria pyricola 
2006 
Greece 
(277) 
 
 
 
  
Sphaerotheca 
clandestina 
2005 
USA 
(278) 
 
 
 
  
Sphaerotheca 
fuligenea  
1981 
Netherlands 
(279) 
 
1982 
Greece 
(280) 
 
1982 
Israel 
(280) 
 
1982 
Jordan 
(280) 
 
1982 
Spain 
(280) 
 
1982 
Syria 
(280) 
 
1983 
Norway 
(279) 
 
1983 
UK 
(279) 
 
1986 
USA 
(281) 
 
1989 
Japan 
(282) 
 
1993 
Australia 
(283) 
 
2001 
Czech Republic 
(224) 
 
2008 
South Korea 
(284) 
 
 
 
  
Sphaerotheca mors-
uvae 
1988 
Poland 
(285) 
 
 
 
  
Sphaerotheca 
pannosa  
1999 
Israel 
(286) 
 
 
 
  
Stagonosporopsis 
2013 
USA 
(287) 
  
52 
caricae 
 
2016 
Brazil  
(287) 
 
 
 
  
Uncinula necator 
1988 
Portugal 
(288) 
 
1989 
France 
(288) 
 
1989 
USA 
(289) 
 
1990 
Italy 
(288) 
 
1996 
Switzerland 
(290) 
 
1996 
Israel 
(290) 
 
1996 
India 
(290) 
 
1996 
Austria 
(291) 
 
1998 
South Africa 
(292) 
 
1998 
Australia 
(293) 
 
2008 
Chile 
(294) 
 
 
 
  
Venturia inaequalis 
1984 
Canada 
(295) 
 
1985 
Germany 
(296) 
 
1985 
France 
(297) 
 
1986 
Italy 
(298) 
 
1988 
USA 
(299) 
 
1990 
New Zealand 
(300) 
 
2000 
Czech Republic 
(301) 
 
2001 
Poland 
(302) 
 
2002 
Australia 
(303) 
 
2007 
UK 
(304) 
 
2008 
Chile 
(305) 
 
2009 
Serbia 
(306) 
 
2010 
Uruguay 
(307) 
 
2016 
Japan 
(214) 
 
 
 
  
Venturia nashicola 
1995 
Japan 
(308) 
 
 
 
  
Zymoseptoria tritici 
1991 
UK 
(309) 
 
1992 
Denmark 
(310) 
 
1993 
France 
(311) 
 
1996 
Germany 
(311) 
 
1999 
Switzerland 
(312) 
 
2003 
Ireland 
(313) 
 
2007 
Belarus 
(314) 
 
2007 
Belgium 
(314) 
 
2007 
Finland 
(314) 
 
2007 
Latvia 
(314) 
 
2007 
Norway 
(314) 
 
2007 
Poland 
(314) 
 
2007 
Sweden 
(314) 
 
2008 
Tunisia 
(315) 
  
53 
 
2009 
Russia 
(316) 
 
2009 
Czech Republic 
(316) 
 
2009 
Austria 
(317) 
 
2009 
Lithuania 
(318) 
 
2012 
Ukraine 
(319) 
 
2012 
USA 
(320) 
 
2012 
Australia 
(321) 
 
2013 
New Zealand 
(322) 
 
2014 
Netherlands 
(214) 
 
2014 
Luxembourg 
(214) 
 
2014 
Estonia 
(323) 
 
2015 
Hungary 
(324) 
 
 
 
  
 
 
 
 
 
1240 
1 Year of collection of earliest resistant isolate where given (latest year in range where only 
1241 
multi-year pooled data are reported); otherwise, year of publication. 
1242 
 
1243 
